{"id": "article-154122_0", "title": "Menstrual Suppression -- Continuing Education Activity", "content": "Medication-induced secondary amenorrhea refers to the deliberate use of hormonal contraceptive medications to suppress menstruation or achieve amenorrhea. Patients or their caregivers may choose menstrual suppression for various reasons, such as reducing menstrual-related symptoms, managing certain health conditions, or improving quality of life. This approach is particularly relevant for special populations including adolescents, individuals with developmental or physical disabilities, military personnel, athletes, and individuals with cancer. The choice of hormonal contraceptives, such as combined hormonal contraceptives, progestin-only contraceptives, long-acting reversible contraceptives, gonadotropin-releasing hormone agonists, or testosterone, depends on individual preferences and health considerations. This activity provides an overview of the indications and methods of menstrual suppression, including considerations for special populations, and highlights the role of clinicians and the interprofessional team in delivering comprehensive care to menstruating individuals.", "contents": "Menstrual Suppression -- Continuing Education Activity. Medication-induced secondary amenorrhea refers to the deliberate use of hormonal contraceptive medications to suppress menstruation or achieve amenorrhea. Patients or their caregivers may choose menstrual suppression for various reasons, such as reducing menstrual-related symptoms, managing certain health conditions, or improving quality of life. This approach is particularly relevant for special populations including adolescents, individuals with developmental or physical disabilities, military personnel, athletes, and individuals with cancer. The choice of hormonal contraceptives, such as combined hormonal contraceptives, progestin-only contraceptives, long-acting reversible contraceptives, gonadotropin-releasing hormone agonists, or testosterone, depends on individual preferences and health considerations. This activity provides an overview of the indications and methods of menstrual suppression, including considerations for special populations, and highlights the role of clinicians and the interprofessional team in delivering comprehensive care to menstruating individuals."}
{"id": "article-154122_1", "title": "Menstrual Suppression -- Continuing Education Activity", "content": "Objectives: Personalize the selection of treatments to achieve menstrual suppression. Recognize the indications and contraindications for menstrual suppression generally and for special populations. Compare and contrast the methods used to induce menstrual suppression. Apply best practices within the interprofessional team to reduce complications and barriers when using menstrual suppression therapy. Access free multiple choice questions on this topic.", "contents": "Menstrual Suppression -- Continuing Education Activity. Objectives: Personalize the selection of treatments to achieve menstrual suppression. Recognize the indications and contraindications for menstrual suppression generally and for special populations. Compare and contrast the methods used to induce menstrual suppression. Apply best practices within the interprofessional team to reduce complications and barriers when using menstrual suppression therapy. Access free multiple choice questions on this topic."}
{"id": "article-154122_2", "title": "Menstrual Suppression -- Introduction", "content": "Menses is the monthly shedding of the endometrial lining within the human menstrual cycle and occurs for approximately 26% of the world\u2019s population. [1] Medication-induced secondary amenorrhea is the use of hormonal contraceptives or other medications to decrease menses or achieve amenorrhea purposefully. [2] Manipulating\u00a0the menstrual cycle is widely known to be safe, and withdrawal bleeding periods that classically\u00a0occur hormonal contraceptive\u00a0use are not required for health.", "contents": "Menstrual Suppression -- Introduction. Menses is the monthly shedding of the endometrial lining within the human menstrual cycle and occurs for approximately 26% of the world\u2019s population. [1] Medication-induced secondary amenorrhea is the use of hormonal contraceptives or other medications to decrease menses or achieve amenorrhea purposefully. [2] Manipulating\u00a0the menstrual cycle is widely known to be safe, and withdrawal bleeding periods that classically\u00a0occur hormonal contraceptive\u00a0use are not required for health."}
{"id": "article-154122_3", "title": "Menstrual Suppression -- Introduction", "content": "There are many personal and medical reasons menstruating persons, or their caregivers, if applicable, may opt for menstrual suppression, including decreasing pain and other perimenstrual symptoms, limiting blood loss, lowering the burden of menstrual hygiene, and improving quality of life. [3] [4] [5]", "contents": "Menstrual Suppression -- Introduction. There are many personal and medical reasons menstruating persons, or their caregivers, if applicable, may opt for menstrual suppression, including decreasing pain and other perimenstrual symptoms, limiting blood loss, lowering the burden of menstrual hygiene, and improving quality of life. [3] [4] [5]"}
{"id": "article-154122_4", "title": "Menstrual Suppression -- Introduction", "content": "Medication-induced secondary amenorrhea may also be utilized in managing other health conditions such as heavy menstrual bleeding, dysmenorrhea, endometriosis, and menstrual-related blood loss in the setting of bleeding diathesis. [3] [4] Additionally, some special populations may benefit from menstrual suppression, including adolescents, persons with developmental or physical disabilities, transgender and gender-diverse individuals, military service members, athletes, and individuals with malignancy. [3] With these potential benefits, primary and gynecologic care providers should counsel their patients on menstrual suppression.", "contents": "Menstrual Suppression -- Introduction. Medication-induced secondary amenorrhea may also be utilized in managing other health conditions such as heavy menstrual bleeding, dysmenorrhea, endometriosis, and menstrual-related blood loss in the setting of bleeding diathesis. [3] [4] Additionally, some special populations may benefit from menstrual suppression, including adolescents, persons with developmental or physical disabilities, transgender and gender-diverse individuals, military service members, athletes, and individuals with malignancy. [3] With these potential benefits, primary and gynecologic care providers should counsel their patients on menstrual suppression."}
{"id": "article-154122_5", "title": "Menstrual Suppression -- Introduction", "content": "Commonly used hormonal contraceptives may be leveraged to achieve menstrual suppression, including continuous or extended use of the combined oral contraceptive pill (OCP), the combined transdermal patch, the combined intravaginal ring, the progestin-only pill, and injectable depot medroxyprogesterone acetate (DMPA), as well as long-acting reversible contraceptives (LARC) such as the levonorgestrel-releasing intrauterine device (IUD), and the subdermal etonogestrel implant. Less commonly used options include gonadotropin-releasing hormone (GnRH) agonists and testosterone.", "contents": "Menstrual Suppression -- Introduction. Commonly used hormonal contraceptives may be leveraged to achieve menstrual suppression, including continuous or extended use of the combined oral contraceptive pill (OCP), the combined transdermal patch, the combined intravaginal ring, the progestin-only pill, and injectable depot medroxyprogesterone acetate (DMPA), as well as long-acting reversible contraceptives (LARC) such as the levonorgestrel-releasing intrauterine device (IUD), and the subdermal etonogestrel implant. Less commonly used options include gonadotropin-releasing hormone (GnRH) agonists and testosterone."}
{"id": "article-154122_6", "title": "Menstrual Suppression -- Introduction", "content": "Complete cessation of menses is challenging, and success\u00a0rates and associated side effects vary between methods. Patients should therefore be counseled on realistic expectations for each method and aim to decrease bleeding days and associated burdens rather than achieve complete amenorrhea.", "contents": "Menstrual Suppression -- Introduction. Complete cessation of menses is challenging, and success\u00a0rates and associated side effects vary between methods. Patients should therefore be counseled on realistic expectations for each method and aim to decrease bleeding days and associated burdens rather than achieve complete amenorrhea."}
{"id": "article-154122_7", "title": "Menstrual Suppression -- Introduction", "content": "The American College of Obstetricians and Gynecologists (ACOG) released a Clinical Consensus on general approaches to menstrual suppression in 2022 to guide clinicians in their patient care and counseling. This review heavily includes and is consistent with recommendations from this Clinical Consensus. [3]", "contents": "Menstrual Suppression -- Introduction. The American College of Obstetricians and Gynecologists (ACOG) released a Clinical Consensus on general approaches to menstrual suppression in 2022 to guide clinicians in their patient care and counseling. This review heavily includes and is consistent with recommendations from this Clinical Consensus. [3]"}
{"id": "article-154122_8", "title": "Menstrual Suppression -- Anatomy and Physiology -- Phases of the Menstrual Cycle", "content": "Menstrual cycles are\u00a0described relative to the onset of menses (ie, the shedding of the endometrial lining), with cycle day one being the onset of heavy menstrual bleeding. The menstrual cycle is divided into two primary phases. [6] Since the biological reproductive cycle consists of cyclic changes in the ovary and uterus, the\u00a02 primary phases of the reproductive cycle can be described according to both the ovarian and uterine cycles.", "contents": "Menstrual Suppression -- Anatomy and Physiology -- Phases of the Menstrual Cycle. Menstrual cycles are\u00a0described relative to the onset of menses (ie, the shedding of the endometrial lining), with cycle day one being the onset of heavy menstrual bleeding. The menstrual cycle is divided into two primary phases. [6] Since the biological reproductive cycle consists of cyclic changes in the ovary and uterus, the\u00a02 primary phases of the reproductive cycle can be described according to both the ovarian and uterine cycles."}
{"id": "article-154122_9", "title": "Menstrual Suppression -- Anatomy and Physiology -- Phases of the Menstrual Cycle", "content": "The first phase is known as the follicular phase in the ovarian cycle or the proliferative phase when describing the uterine cycle; it begins at the onset of menses and continues until ovulation . The second phase, known as the luteal phase in the ovarian cycle and the secretory phase in the uterine cycle, begins at ovulation and continues until the onset of the next menses. These cycles\u00a0are regulated by the interplay of estrogen, progesterone, follicular stimulating hormone (FSH), luteinizing hormone (LH), and gonadotropin-releasing hormone (GnRH) within the hypothalamic-pituitary-ovarian (HPO) axis.", "contents": "Menstrual Suppression -- Anatomy and Physiology -- Phases of the Menstrual Cycle. The first phase is known as the follicular phase in the ovarian cycle or the proliferative phase when describing the uterine cycle; it begins at the onset of menses and continues until ovulation . The second phase, known as the luteal phase in the ovarian cycle and the secretory phase in the uterine cycle, begins at ovulation and continues until the onset of the next menses. These cycles\u00a0are regulated by the interplay of estrogen, progesterone, follicular stimulating hormone (FSH), luteinizing hormone (LH), and gonadotropin-releasing hormone (GnRH) within the hypothalamic-pituitary-ovarian (HPO) axis."}
{"id": "article-154122_10", "title": "Menstrual Suppression -- Anatomy and Physiology -- Physiology of the Menstrual Cycle", "content": "In the follicular phase, GnRH pulses trigger the anterior pituitary gland to release FSH, which stimulates ovarian follicles to mature and produce estrogen. This estrogen stimulates the growth of the endometrium and provides feedback inhibition at the level of the pituitary (meaning that as estrogen levels rise during the follicular phase, FSH levels begin to decline).\u00a0As FSH levels decline during the follicular phase, most developing follicles undergo atresia, and (usually) a single dominant follicle persists. At the end of the follicular phase, estrogen's effect on the pituitary switches from inhibitory to stimulatory, resulting in a surge of LH from the pituitary, which triggers ovulation.", "contents": "Menstrual Suppression -- Anatomy and Physiology -- Physiology of the Menstrual Cycle. In the follicular phase, GnRH pulses trigger the anterior pituitary gland to release FSH, which stimulates ovarian follicles to mature and produce estrogen. This estrogen stimulates the growth of the endometrium and provides feedback inhibition at the level of the pituitary (meaning that as estrogen levels rise during the follicular phase, FSH levels begin to decline).\u00a0As FSH levels decline during the follicular phase, most developing follicles undergo atresia, and (usually) a single dominant follicle persists. At the end of the follicular phase, estrogen's effect on the pituitary switches from inhibitory to stimulatory, resulting in a surge of LH from the pituitary, which triggers ovulation."}
{"id": "article-154122_11", "title": "Menstrual Suppression -- Anatomy and Physiology -- Physiology of the Menstrual Cycle", "content": "After the release of the oocyte and under stimulation from LH, the now-empty follicle is transformed into the corpus luteum , which begins secreting progesterone. Generally speaking, natural progesterone causes maturation and stabilization of the endometrium. While the follicular phase may last a variable amount of time until a follicle matures and ovulation occurs, the persistence of the corpus luteum (and thus the luteal phase) is generally much more consistent in duration, lasting about two weeks. If pregnancy does not occur within the first few days after ovulation, estrogen and progesterone levels decline in the second half of the luteal phase (approximately days 21 through 28), and this hormone decrease ultimately triggers menses. [6] Without exogenous hormones , periodic menses are essential to prevent \"build-up\" and hyperplasia of the endometrium.", "contents": "Menstrual Suppression -- Anatomy and Physiology -- Physiology of the Menstrual Cycle. After the release of the oocyte and under stimulation from LH, the now-empty follicle is transformed into the corpus luteum , which begins secreting progesterone. Generally speaking, natural progesterone causes maturation and stabilization of the endometrium. While the follicular phase may last a variable amount of time until a follicle matures and ovulation occurs, the persistence of the corpus luteum (and thus the luteal phase) is generally much more consistent in duration, lasting about two weeks. If pregnancy does not occur within the first few days after ovulation, estrogen and progesterone levels decline in the second half of the luteal phase (approximately days 21 through 28), and this hormone decrease ultimately triggers menses. [6] Without exogenous hormones , periodic menses are essential to prevent \"build-up\" and hyperplasia of the endometrium."}
{"id": "article-154122_12", "title": "Menstrual Suppression -- Anatomy and Physiology -- From Menarche to Mature Menstrual Cycles", "content": "The start of menstrual cycles and menses is deemed menarche and typically begins between 10 and 15 years of age. [6] [7] Biologically female adolescents are at high risk for menstrual dysfunction due to immaturity of the HPO axis resulting in anovulatory cycles, particularly in the first two years post-menarche. [8] [9] Anovulatory cycles are associated with irregular cycle length (ranging from 20 to 90 days) and heavy or prolonged menstrual bleeding. [10]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- From Menarche to Mature Menstrual Cycles. The start of menstrual cycles and menses is deemed menarche and typically begins between 10 and 15 years of age. [6] [7] Biologically female adolescents are at high risk for menstrual dysfunction due to immaturity of the HPO axis resulting in anovulatory cycles, particularly in the first two years post-menarche. [8] [9] Anovulatory cycles are associated with irregular cycle length (ranging from 20 to 90 days) and heavy or prolonged menstrual bleeding. [10]"}
{"id": "article-154122_13", "title": "Menstrual Suppression -- Anatomy and Physiology -- From Menarche to Mature Menstrual Cycles", "content": "Despite this, up to 90% of cycles will still be between 21 and 45 days long. [7] As the HPO axis matures over 1 to 2 years post-menarche, ovulation and the menstrual cycle become more regular; by the third year post-menarche, 60 to 80% of adolescents have 21 to 34 day cycles, comparable to typical adults. [7] [8]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- From Menarche to Mature Menstrual Cycles. Despite this, up to 90% of cycles will still be between 21 and 45 days long. [7] As the HPO axis matures over 1 to 2 years post-menarche, ovulation and the menstrual cycle become more regular; by the third year post-menarche, 60 to 80% of adolescents have 21 to 34 day cycles, comparable to typical adults. [7] [8]"}
{"id": "article-154122_14", "title": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea", "content": "Suppression\u00a0or cessation of\u00a0menses is achieved by inducing significant structural changes to the endometrial lining through glandular atrophy or decidualization. Combined hormonal contraceptives (CHCs), which include estrogen and progestin, such as OCPs, the transdermal patch, and the intravaginal ring, prevent the growth of the endometrium in two significant ways. First, they\u00a0inhibit the release of FSH and LH within the\u00a0HPO\u00a0axis; the suppression of FSH decreases estrogen, depriving the endometrium of its primary \"growth factor.\" [11] [12]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea. Suppression\u00a0or cessation of\u00a0menses is achieved by inducing significant structural changes to the endometrial lining through glandular atrophy or decidualization. Combined hormonal contraceptives (CHCs), which include estrogen and progestin, such as OCPs, the transdermal patch, and the intravaginal ring, prevent the growth of the endometrium in two significant ways. First, they\u00a0inhibit the release of FSH and LH within the\u00a0HPO\u00a0axis; the suppression of FSH decreases estrogen, depriving the endometrium of its primary \"growth factor.\" [11] [12]"}
{"id": "article-154122_15", "title": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea", "content": "Additionally, synthetic progestins do not have the same effects on the endometrium as natural progesterone. Synthetic progestins tend to be more androgenic, and continuous exposure generally leads to endometrial glandular atrophy. [13] These progestins are found in CHCs,\u00a0progestin-only pills, levonorgestrel-releasing IUDs, and etonogestrel implants.\u00a0DMPA also suppresses menses by causing decidualization of the endometrium and inhibiting gonadotropin secretion from the pituitary. [14] [15]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea. Additionally, synthetic progestins do not have the same effects on the endometrium as natural progesterone. Synthetic progestins tend to be more androgenic, and continuous exposure generally leads to endometrial glandular atrophy. [13] These progestins are found in CHCs,\u00a0progestin-only pills, levonorgestrel-releasing IUDs, and etonogestrel implants.\u00a0DMPA also suppresses menses by causing decidualization of the endometrium and inhibiting gonadotropin secretion from the pituitary. [14] [15]"}
{"id": "article-154122_16", "title": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea", "content": "Given these mechanisms of action, there is no \"build-up\" of endometrial tissue within the uterus with contraceptive use. Any bleeding occurs from hormonal withdrawal or breakthrough bleeding from a \"fragile\" atrophic endometrium rather than true physiologic shedding of the endometrial lining. [12] [3] [4]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea. Given these mechanisms of action, there is no \"build-up\" of endometrial tissue within the uterus with contraceptive use. Any bleeding occurs from hormonal withdrawal or breakthrough bleeding from a \"fragile\" atrophic endometrium rather than true physiologic shedding of the endometrial lining. [12] [3] [4]"}
{"id": "article-154122_17", "title": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea", "content": "The classic use of a placebo week with non-LARC contraceptive methods to precipitate withdrawal bleeding to mimic the \"natural lunar cycle\" of menses is a historical remnant based on the social and cultural norms of women during the era in which hormonal contraceptives were developed \u2013 it is not based on biological need, nor is it required for health. [12] [3] [4]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea. The classic use of a placebo week with non-LARC contraceptive methods to precipitate withdrawal bleeding to mimic the \"natural lunar cycle\" of menses is a historical remnant based on the social and cultural norms of women during the era in which hormonal contraceptives were developed \u2013 it is not based on biological need, nor is it required for health. [12] [3] [4]"}
{"id": "article-154122_18", "title": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea", "content": "By causing endometrial atrophy, menstrual suppression may also be beneficial in treating heavy menstrual bleeding, dysmenorrhea, endometriosis, and menstrual-related blood loss in the setting of bleeding diathesis, as discussed in Indications . [12] [3] [5] Evidence suggests contraceptive use protects against endometrial, ovarian, and colorectal cancers (as described in a 2017 study of 46,000 women, specifically using OCPs). [16]", "contents": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea. By causing endometrial atrophy, menstrual suppression may also be beneficial in treating heavy menstrual bleeding, dysmenorrhea, endometriosis, and menstrual-related blood loss in the setting of bleeding diathesis, as discussed in Indications . [12] [3] [5] Evidence suggests contraceptive use protects against endometrial, ovarian, and colorectal cancers (as described in a 2017 study of 46,000 women, specifically using OCPs). [16]"}
{"id": "article-154122_19", "title": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea", "content": "Upon discontinuation of CHCs\u00a0or LARC, normal HPO axis function returns, and endometrial growth resumes, though this may take several months. [17] [11] Additionally, a 2018 systematic review and meta-analysis of over 14,800 women concluded no evidence of impact on baseline fertility with either the use of IUDs or long-term use of contraception. The pregnancy rate within 12 months of contraception discontinuation in this review was 83%, which\u00a0was only slightly lower than that of non-hormone users (who had rates of 85-94%), and the authors theorize this is due to the temporary delay in the return of ovulation after stopping hormonal contraceptives. [17] Long-term fertility rates are not affected. [3] The uses and efficacies of each suppression method vary (see Techniques ).", "contents": "Menstrual Suppression -- Anatomy and Physiology -- The Physiology of Medication-Induced Secondary Amenorrhea. Upon discontinuation of CHCs\u00a0or LARC, normal HPO axis function returns, and endometrial growth resumes, though this may take several months. [17] [11] Additionally, a 2018 systematic review and meta-analysis of over 14,800 women concluded no evidence of impact on baseline fertility with either the use of IUDs or long-term use of contraception. The pregnancy rate within 12 months of contraception discontinuation in this review was 83%, which\u00a0was only slightly lower than that of non-hormone users (who had rates of 85-94%), and the authors theorize this is due to the temporary delay in the return of ovulation after stopping hormonal contraceptives. [17] Long-term fertility rates are not affected. [3] The uses and efficacies of each suppression method vary (see Techniques )."}
{"id": "article-154122_20", "title": "Menstrual Suppression -- Indications", "content": "If desired, individuals who menstruate or their caregivers may choose to pursue menstrual suppression for personal or medical reasons. Notably, a study revealed that as many as 59% of women in the United States expressed a desire to eliminate their monthly periods. [18]", "contents": "Menstrual Suppression -- Indications. If desired, individuals who menstruate or their caregivers may choose to pursue menstrual suppression for personal or medical reasons. Notably, a study revealed that as many as 59% of women in the United States expressed a desire to eliminate their monthly periods. [18]"}
{"id": "article-154122_21", "title": "Menstrual Suppression -- Indications", "content": "For average adults, reasons for suppression include decreasing bleeding, pain, and other perimenstrual symptoms, improving quality of life, managing certain medical conditions, lowering the burdens of menstrual hygiene, and decreasing the use of disposable hygiene products. [4] [5] Additional benefits in special populations must also be considered, as discussed below.", "contents": "Menstrual Suppression -- Indications. For average adults, reasons for suppression include decreasing bleeding, pain, and other perimenstrual symptoms, improving quality of life, managing certain medical conditions, lowering the burdens of menstrual hygiene, and decreasing the use of disposable hygiene products. [4] [5] Additional benefits in special populations must also be considered, as discussed below."}
{"id": "article-154122_22", "title": "Menstrual Suppression -- Indications -- Management of Menstrual Symptoms", "content": "Menstrual-related symptoms such as heavy menstrual bleeding, dysmenorrhea (excessive pain associated with menses), and premenstrual syndrome impact up to 2.5 million biologically female adults annually and may lead to absenteeism from school or work and decreased participation in social, athletic, professional, or recreational activities. [4] [19]", "contents": "Menstrual Suppression -- Indications -- Management of Menstrual Symptoms. Menstrual-related symptoms such as heavy menstrual bleeding, dysmenorrhea (excessive pain associated with menses), and premenstrual syndrome impact up to 2.5 million biologically female adults annually and may lead to absenteeism from school or work and decreased participation in social, athletic, professional, or recreational activities. [4] [19]"}
{"id": "article-154122_23", "title": "Menstrual Suppression -- Indications -- Management of Menstrual Symptoms", "content": "Therefore, individuals may prefer to suppress menses to decrease the burdens of pain, bleeding, and other symptoms such as bloating, fatigue, and mood changes. Some individuals may also desire to control when and where their menses occur rather than experiencing regular monthly or irregular menses. [4] [2] [5] [12]", "contents": "Menstrual Suppression -- Indications -- Management of Menstrual Symptoms. Therefore, individuals may prefer to suppress menses to decrease the burdens of pain, bleeding, and other symptoms such as bloating, fatigue, and mood changes. Some individuals may also desire to control when and where their menses occur rather than experiencing regular monthly or irregular menses. [4] [2] [5] [12]"}
{"id": "article-154122_24", "title": "Menstrual Suppression -- Indications -- Management of Menstrual Symptoms", "content": "Several studies suggest that individuals may prefer to delay, suppress or completely stop their period for an improved quality of life, including up to 65% of female college students and up to 86% of female military personnel. [20] [12] [21] The greatest desire for suppression is observed in the youngest and oldest menstruating individuals compared to those in middle reproductive age. [22] This preference varies between global regions, with a higher preference for amenorrhea in North America, South America, and Europe and a lower preference in the Middle East and Africa. [22] [12]", "contents": "Menstrual Suppression -- Indications -- Management of Menstrual Symptoms. Several studies suggest that individuals may prefer to delay, suppress or completely stop their period for an improved quality of life, including up to 65% of female college students and up to 86% of female military personnel. [20] [12] [21] The greatest desire for suppression is observed in the youngest and oldest menstruating individuals compared to those in middle reproductive age. [22] This preference varies between global regions, with a higher preference for amenorrhea in North America, South America, and Europe and a lower preference in the Middle East and Africa. [22] [12]"}
{"id": "article-154122_25", "title": "Menstrual Suppression -- Indications -- Management of Other Medical Conditions", "content": "Menstrual suppression may also be utilized for other health conditions, such as managing endometriosis, decreasing blood loss related to bleeding diathesis (particularly von Willebrand disease), and reducing the risk for or worsening of present anemia. [12] [3] [5] Up to 15% of iron deficiency anemia diagnoses are associated with \"disorders of menstruation\" and \"other abnormal bleeding from the female genital tract\"; achieving amenorrhea improves average iron levels in menstruating persons. [20]", "contents": "Menstrual Suppression -- Indications -- Management of Other Medical Conditions. Menstrual suppression may also be utilized for other health conditions, such as managing endometriosis, decreasing blood loss related to bleeding diathesis (particularly von Willebrand disease), and reducing the risk for or worsening of present anemia. [12] [3] [5] Up to 15% of iron deficiency anemia diagnoses are associated with \"disorders of menstruation\" and \"other abnormal bleeding from the female genital tract\"; achieving amenorrhea improves average iron levels in menstruating persons. [20]"}
{"id": "article-154122_26", "title": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene", "content": "Decreasing menstrual hygiene's contribution to global inequality and environmental degradation is also important to consider.", "contents": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene. Decreasing menstrual hygiene's contribution to global inequality and environmental degradation is also important to consider."}
{"id": "article-154122_27", "title": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene", "content": "Approximately 800 million individuals menstruate on any given day, requiring them to have reliable access to menstrual hygiene products (pads, tampons, menstrual cups, or panties), clean water, and private sanitation facilities. [1] Unfortunately, many people around the world who\u00a0menstruate do not have access to these resources \u2013 a global inequity deemed \"period poverty\" \u2013 which may contribute to a disproportionately higher rate of school or work absenteeism, embarrassment, social ostracization, and risk for vaginal or urinary tract infection. [1] [4]", "contents": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene. Approximately 800 million individuals menstruate on any given day, requiring them to have reliable access to menstrual hygiene products (pads, tampons, menstrual cups, or panties), clean water, and private sanitation facilities. [1] Unfortunately, many people around the world who\u00a0menstruate do not have access to these resources \u2013 a global inequity deemed \"period poverty\" \u2013 which may contribute to a disproportionately higher rate of school or work absenteeism, embarrassment, social ostracization, and risk for vaginal or urinary tract infection. [1] [4]"}
{"id": "article-154122_28", "title": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene", "content": "If access to menstrual suppression options can be achieved and the number of bleeding days decreased, it could decrease these burdens on populations suffering from period poverty. For example, in well-developed countries, an individual without a reliable income may have access to hormonal contraceptives through a government-sponsored health plan but may lack dedicated funds to purchase menstrual hygiene products.", "contents": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene. If access to menstrual suppression options can be achieved and the number of bleeding days decreased, it could decrease these burdens on populations suffering from period poverty. For example, in well-developed countries, an individual without a reliable income may have access to hormonal contraceptives through a government-sponsored health plan but may lack dedicated funds to purchase menstrual hygiene products."}
{"id": "article-154122_29", "title": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene", "content": "Additionally, several populations may face unique challenges associated with menstrual hygiene, including deployed military members, people working in remote locations, those who struggle with housing insecurity, or incarcerated individuals. [3]", "contents": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene. Additionally, several populations may face unique challenges associated with menstrual hygiene, including deployed military members, people working in remote locations, those who struggle with housing insecurity, or incarcerated individuals. [3]"}
{"id": "article-154122_30", "title": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene", "content": "There is also significant monetary cost and environmental waste associated with menstrual hygiene products. Decreasing bleeding days may assist in lowering this personal cost\u00a0and reduce the global environmental impact of single-use synthetic materials used and disposed of during menses. [1]", "contents": "Menstrual Suppression -- Indications -- Lowering the Burdens of Menstrual Hygiene. There is also significant monetary cost and environmental waste associated with menstrual hygiene products. Decreasing bleeding days may assist in lowering this personal cost\u00a0and reduce the global environmental impact of single-use synthetic materials used and disposed of during menses. [1]"}
{"id": "article-154122_31", "title": "Menstrual Suppression -- Indications -- Adolescents", "content": "Adolescents are at high risk for menstrual dysfunction, especially in the first 1 to 2 years post-menarche. [8] The recommendation\u00a0is that clinicians who care for adolescents discuss pubertal development and menarche during annual wellness exams starting as early as age eight. [7] . Due to anovulatory cycles, adolescents are prone to variable cycle lengths, heavy menstrual bleeding, and prolonged menstrual bleeding.", "contents": "Menstrual Suppression -- Indications -- Adolescents. Adolescents are at high risk for menstrual dysfunction, especially in the first 1 to 2 years post-menarche. [8] The recommendation\u00a0is that clinicians who care for adolescents discuss pubertal development and menarche during annual wellness exams starting as early as age eight. [7] . Due to anovulatory cycles, adolescents are prone to variable cycle lengths, heavy menstrual bleeding, and prolonged menstrual bleeding."}
{"id": "article-154122_32", "title": "Menstrual Suppression -- Indications -- Adolescents", "content": "Adolescents, with or without the involvement of a parent or caregiver, may opt for menstrual suppression for several reasons. Menstrual suppression may be useful in helping regulate the HPO axis and prevent highly irregular cycles and associated stress. [23] Adolescents, like adults, may desire menstrual suppression to decrease menstrual-related symptoms such as pain, bloating, and fatigue. They may also wish to decrease their menstrual hygiene burdens while attending school, where access to menstrual hygiene supplies can be difficult or be accompanied by social stressors or embarrassment. They\u00a0often desire control over the timing of menses for special events, such as camp, graduation, travel, or competitive sporting events (or possibly entire sports seasons). [23] [4] [23] Menstrual suppression has also been proposed as a management adjunct for adolescents with chronic headaches, particularly if the headaches occur near the time of menses. [23]", "contents": "Menstrual Suppression -- Indications -- Adolescents. Adolescents, with or without the involvement of a parent or caregiver, may opt for menstrual suppression for several reasons. Menstrual suppression may be useful in helping regulate the HPO axis and prevent highly irregular cycles and associated stress. [23] Adolescents, like adults, may desire menstrual suppression to decrease menstrual-related symptoms such as pain, bloating, and fatigue. They may also wish to decrease their menstrual hygiene burdens while attending school, where access to menstrual hygiene supplies can be difficult or be accompanied by social stressors or embarrassment. They\u00a0often desire control over the timing of menses for special events, such as camp, graduation, travel, or competitive sporting events (or possibly entire sports seasons). [23] [4] [23] Menstrual suppression has also been proposed as a management adjunct for adolescents with chronic headaches, particularly if the headaches occur near the time of menses. [23]"}
{"id": "article-154122_33", "title": "Menstrual Suppression -- Indications -- Adolescents", "content": "The American Academy of Pediatrics (AAP) does not recommend a routine pelvic exam before initiating menstrual suppression in individuals\u00a0younger than 21 years if normal menstruation occurs. [24]", "contents": "Menstrual Suppression -- Indications -- Adolescents. The American Academy of Pediatrics (AAP) does not recommend a routine pelvic exam before initiating menstrual suppression in individuals\u00a0younger than 21 years if normal menstruation occurs. [24]"}
{"id": "article-154122_34", "title": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability", "content": "Clinicians should discuss menses and menstrual management with adolescents\u00a0and adults with developmental or physical disabilities and their caregivers, if applicable, ideally before menarche. [25] [26] [27] One must understand both the individual's and caregiver's motivations for menstrual suppression and establish clear expectations and treatment goals. [28] [25] [29] Clinicians should maximize patient autonomy as much as possible based on their cognitive abilities. [27]", "contents": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability. Clinicians should discuss menses and menstrual management with adolescents\u00a0and adults with developmental or physical disabilities and their caregivers, if applicable, ideally before menarche. [25] [26] [27] One must understand both the individual's and caregiver's motivations for menstrual suppression and establish clear expectations and treatment goals. [28] [25] [29] Clinicians should maximize patient autonomy as much as possible based on their cognitive abilities. [27]"}
{"id": "article-154122_35", "title": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability", "content": "A 2021 retrospective cohort study of adolescents and young women with disabilities found that the primary reasons for seeking menstrual suppression were irregular menstrual bleeding, heavy menstrual bleeding, hygiene burden, inconvenience of menses, dysmenorrhea, and assistance in managing comorbid conditions such as behavioral issues and catamenial epilepsy. [30] Caregivers, however, are often primarily concerned with hygiene burdens, menstrual-related symptoms, and management of difficult behavior. [31] [26] Quality of life, school attendance, participation in recreational and social activities, and pregnancy prevention should also be considered. [26] [26]", "contents": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability. A 2021 retrospective cohort study of adolescents and young women with disabilities found that the primary reasons for seeking menstrual suppression were irregular menstrual bleeding, heavy menstrual bleeding, hygiene burden, inconvenience of menses, dysmenorrhea, and assistance in managing comorbid conditions such as behavioral issues and catamenial epilepsy. [30] Caregivers, however, are often primarily concerned with hygiene burdens, menstrual-related symptoms, and management of difficult behavior. [31] [26] Quality of life, school attendance, participation in recreational and social activities, and pregnancy prevention should also be considered. [26] [26]"}
{"id": "article-154122_36", "title": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability", "content": "Menstrual suppression should not be initiated before menarche to ensure the appropriate onset of menarche and pubertal development. [26] [32] However, anticipatory guidance for patients and caregivers can help reduce anxiety regarding menstruation. Before initiating menstrual suppression, the individual's medical and menstrual history should be considered to evaluate for and rule out underlying metabolic, hormonal, or other pathology\u00a0that may contribute to menstrual dysfunction.", "contents": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability. Menstrual suppression should not be initiated before menarche to ensure the appropriate onset of menarche and pubertal development. [26] [32] However, anticipatory guidance for patients and caregivers can help reduce anxiety regarding menstruation. Before initiating menstrual suppression, the individual's medical and menstrual history should be considered to evaluate for and rule out underlying metabolic, hormonal, or other pathology\u00a0that may contribute to menstrual dysfunction."}
{"id": "article-154122_37", "title": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability", "content": "Medication reconciliation is also key in this population. Some medication classes frequently utilized in the setting of developmental or physical disabilities\u00a0can have significant drug interactions with\u00a0hormonal\u00a0contraceptives (see Contraindications ). [28] [26] [32] For example, enzyme-inducing anti-epileptic drugs interact with all estrogen-containing methods, as well as with oral progestins. [26]", "contents": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability. Medication reconciliation is also key in this population. Some medication classes frequently utilized in the setting of developmental or physical disabilities\u00a0can have significant drug interactions with\u00a0hormonal\u00a0contraceptives (see Contraindications ). [28] [26] [32] For example, enzyme-inducing anti-epileptic drugs interact with all estrogen-containing methods, as well as with oral progestins. [26]"}
{"id": "article-154122_38", "title": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability", "content": "Other considerations include a person's mobility, ability to swallow pills, cognitive ability to understand menses, and menstrual hygiene. For example, when individuals have limited mobility, their risk of venous thromboembolic events (VTE) may be uncertain, they may have lower bone mineral density, and even small amounts of weight gain may impact their ability to transfer themselves from a wheelchair. For these reasons, the American Academy of Pediatrics recommends careful individual assessment and joint decision-making to determine the most appropriate menstrual suppression method for adolescents with disabilities. [26]", "contents": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability. Other considerations include a person's mobility, ability to swallow pills, cognitive ability to understand menses, and menstrual hygiene. For example, when individuals have limited mobility, their risk of venous thromboembolic events (VTE) may be uncertain, they may have lower bone mineral density, and even small amounts of weight gain may impact their ability to transfer themselves from a wheelchair. For these reasons, the American Academy of Pediatrics recommends careful individual assessment and joint decision-making to determine the most appropriate menstrual suppression method for adolescents with disabilities. [26]"}
{"id": "article-154122_39", "title": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability", "content": "Lastly and importantly,\u00a0clinicians\u00a0should evaluate the risk of pregnancy and assess the risk of sexual abuse (by caregivers or others) in all adolescents and adults with developmental or physical disabilities before initiation of menstrual suppression. [26] [33]", "contents": "Menstrual Suppression -- Indications -- People\u00a0with Developmental or Physical Disability. Lastly and importantly,\u00a0clinicians\u00a0should evaluate the risk of pregnancy and assess the risk of sexual abuse (by caregivers or others) in all adolescents and adults with developmental or physical disabilities before initiation of menstrual suppression. [26] [33]"}
{"id": "article-154122_40", "title": "Menstrual Suppression -- Indications -- Transgender and Gender-Diverse\u00a0Individuals", "content": "In transgender and gender-diverse adolescents and adults, menses can be a significant source of distress; therefore, menstrual suppression may be an important intervention in gender-affirming care. [34] [35] Menstrual suppression for these individuals should be initiated with a multidisciplinary team (see Enhancing Healthcare Team Outcomes ), which\u00a0may begin before menarche in this select population. [32] [36]", "contents": "Menstrual Suppression -- Indications -- Transgender and Gender-Diverse\u00a0Individuals. In transgender and gender-diverse adolescents and adults, menses can be a significant source of distress; therefore, menstrual suppression may be an important intervention in gender-affirming care. [34] [35] Menstrual suppression for these individuals should be initiated with a multidisciplinary team (see Enhancing Healthcare Team Outcomes ), which\u00a0may begin before menarche in this select population. [32] [36]"}
{"id": "article-154122_41", "title": "Menstrual Suppression -- Indications -- Transgender and Gender-Diverse\u00a0Individuals", "content": "Understanding the motivation for and desired outcome of menstrual suppression is important, as it will guide the treatment method. Often, the goal is to achieve complete amenorrhea to help reduce menstrual-related gender dysphoria, though individuals may also desire contraception or management of menstrual-related symptoms. [34] GnRH agonists and testosterone are commonly selected in this setting, particularly\u00a0when patients prefer a non-estrogen-containing option; however, it must be noted that these medications are not adequate forms of contraception when used alone. [37] [32]", "contents": "Menstrual Suppression -- Indications -- Transgender and Gender-Diverse\u00a0Individuals. Understanding the motivation for and desired outcome of menstrual suppression is important, as it will guide the treatment method. Often, the goal is to achieve complete amenorrhea to help reduce menstrual-related gender dysphoria, though individuals may also desire contraception or management of menstrual-related symptoms. [34] GnRH agonists and testosterone are commonly selected in this setting, particularly\u00a0when patients prefer a non-estrogen-containing option; however, it must be noted that these medications are not adequate forms of contraception when used alone. [37] [32]"}
{"id": "article-154122_42", "title": "Menstrual Suppression -- Indications -- Military Personnel and Athletes", "content": "As of 2020, nearly 17% of US Army service members are biologically female, and as of 2016, all combat jobs are open to both male and female individuals. [20] Unique challenges are faced by menstruating military personnel, including operational assignments with high levels of stress, travel and performance demands, unclean field environments, lack of access to adequate sanitation facilities or hygiene products, lack of privacy, difficulty conducting hygiene due to required wear of body armor or other equipment, and the inconvenience of bleeding and other menstrual symptoms in the field and deployed environments. [38] [20] [2]", "contents": "Menstrual Suppression -- Indications -- Military Personnel and Athletes. As of 2020, nearly 17% of US Army service members are biologically female, and as of 2016, all combat jobs are open to both male and female individuals. [20] Unique challenges are faced by menstruating military personnel, including operational assignments with high levels of stress, travel and performance demands, unclean field environments, lack of access to adequate sanitation facilities or hygiene products, lack of privacy, difficulty conducting hygiene due to required wear of body armor or other equipment, and the inconvenience of bleeding and other menstrual symptoms in the field and deployed environments. [38] [20] [2]"}
{"id": "article-154122_43", "title": "Menstrual Suppression -- Indications -- Military Personnel and Athletes", "content": "Up to 86% of menstruating military personnel report a desire for amenorrhea during deployment for these reasons; however, as few as 7% utilize menstrual suppression methods, and only a third report being counseled by a healthcare provider regarding menstrual suppression options. [20] [2] Menstrual suppression may be beneficial to decrease menstrual-related burdens on service members and improve the military force's health and readiness. [20]", "contents": "Menstrual Suppression -- Indications -- Military Personnel and Athletes. Up to 86% of menstruating military personnel report a desire for amenorrhea during deployment for these reasons; however, as few as 7% utilize menstrual suppression methods, and only a third report being counseled by a healthcare provider regarding menstrual suppression options. [20] [2] Menstrual suppression may be beneficial to decrease menstrual-related burdens on service members and improve the military force's health and readiness. [20]"}
{"id": "article-154122_44", "title": "Menstrual Suppression -- Indications -- Military Personnel and Athletes", "content": "Competitive athletes may face similar challenges in managing menses, such as the need for high performance,\u00a0elevated stress levels, frequent travel, and the inconvenience of menstrual symptoms during competition. Menstruating athletes, including adolescents, may choose to manipulate or suppress their menstrual cycle to maximize performance. [4] [3]", "contents": "Menstrual Suppression -- Indications -- Military Personnel and Athletes. Competitive athletes may face similar challenges in managing menses, such as the need for high performance,\u00a0elevated stress levels, frequent travel, and the inconvenience of menstrual symptoms during competition. Menstruating athletes, including adolescents, may choose to manipulate or suppress their menstrual cycle to maximize performance. [4] [3]"}
{"id": "article-154122_45", "title": "Menstrual Suppression -- Indications -- Military Personnel and Athletes", "content": "In these populations, clinicians must carefully consider the effects of continuous hormonal contraceptive use on bone health and the risk of bone stress injury due to the higher risk of low bone mineral density (BMD) and fractures (see Complications ). [38] [39]", "contents": "Menstrual Suppression -- Indications -- Military Personnel and Athletes. In these populations, clinicians must carefully consider the effects of continuous hormonal contraceptive use on bone health and the risk of bone stress injury due to the higher risk of low bone mineral density (BMD) and fractures (see Complications ). [38] [39]"}
{"id": "article-154122_46", "title": "Menstrual Suppression -- Indications -- Active\u00a0Malignancy", "content": "Individuals with active malignancy are at risk of thrombocytopenia from malignancy and chemotherapy, radiation, or stem cell or bone marrow transplantation. [28] This thrombocytopenia may cause heavy menstrual bleeding in up to 40% of oncologic patients, potentially leading to the need for transfusion, hospitalization, or delay in cancer treatment. [28] Clinicians should consider discussing menstrual suppression before starting cancer treatments in menstruating adults and adolescents. [28]", "contents": "Menstrual Suppression -- Indications -- Active\u00a0Malignancy. Individuals with active malignancy are at risk of thrombocytopenia from malignancy and chemotherapy, radiation, or stem cell or bone marrow transplantation. [28] This thrombocytopenia may cause heavy menstrual bleeding in up to 40% of oncologic patients, potentially leading to the need for transfusion, hospitalization, or delay in cancer treatment. [28] Clinicians should consider discussing menstrual suppression before starting cancer treatments in menstruating adults and adolescents. [28]"}
{"id": "article-154122_47", "title": "Menstrual Suppression -- Indications -- Active\u00a0Malignancy", "content": "These individuals will most likely require a progesterone-only method (progestin-only pills or LARC) or a GnRH agonist for suppression, as estrogen-containing products are generally contraindicated in the setting of\u00a0an\u00a0increased risk for thromboembolism (see Contraindications ). [28] [4] Despite this, the US Medical Eligibility Criteria classifies CHCs as category 1 (\"No restrictions for use\") in the setting of endometrial and ovarian cancers awaiting treatment, due in part to the fact that pregnancy would increase a person's overall risk and definitive surgical treatment of these cancers obviates the need for further menstrual suppression. [40] Notably, persons with a current or prior history of breast cancer should not utilize estrogen-containing contraceptives (see Contraindications ). [4] GnRH agonists (primarily leuprolide acetate and triptorelin) are preferred for adolescent oncologic patients due to demonstrated amenorrhea rates as high as 96%. [32]", "contents": "Menstrual Suppression -- Indications -- Active\u00a0Malignancy. These individuals will most likely require a progesterone-only method (progestin-only pills or LARC) or a GnRH agonist for suppression, as estrogen-containing products are generally contraindicated in the setting of\u00a0an\u00a0increased risk for thromboembolism (see Contraindications ). [28] [4] Despite this, the US Medical Eligibility Criteria classifies CHCs as category 1 (\"No restrictions for use\") in the setting of endometrial and ovarian cancers awaiting treatment, due in part to the fact that pregnancy would increase a person's overall risk and definitive surgical treatment of these cancers obviates the need for further menstrual suppression. [40] Notably, persons with a current or prior history of breast cancer should not utilize estrogen-containing contraceptives (see Contraindications ). [4] GnRH agonists (primarily leuprolide acetate and triptorelin) are preferred for adolescent oncologic patients due to demonstrated amenorrhea rates as high as 96%. [32]"}
{"id": "article-154122_48", "title": "Menstrual Suppression -- Contraindications", "content": "Contraindications to menstrual suppression align with the general contraindications for hormonal contraceptives.", "contents": "Menstrual Suppression -- Contraindications. Contraindications to menstrual suppression align with the general contraindications for hormonal contraceptives."}
{"id": "article-154122_49", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Estrogen-Containing Contraceptives", "content": "In the setting of medical comorbidities that may increase the risk of thromboembolism (including pulmonary embolism [PE], deep venous thrombosis [DVT], or stroke), estrogen-containing contraceptives are contraindicated. These conditions include: Hypercoagulable disorders (such as Factor V Liden deficiency) Active liver disease Migraine with aura Active smoking (particularly if over the age of 35) Valvular heart disease Diabetes with vascular sequelae Peripheral or cerebrovascular disease Prior history of PE, DVT, or stroke. [4]", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Estrogen-Containing Contraceptives. In the setting of medical comorbidities that may increase the risk of thromboembolism (including pulmonary embolism [PE], deep venous thrombosis [DVT], or stroke), estrogen-containing contraceptives are contraindicated. These conditions include: Hypercoagulable disorders (such as Factor V Liden deficiency) Active liver disease Migraine with aura Active smoking (particularly if over the age of 35) Valvular heart disease Diabetes with vascular sequelae Peripheral or cerebrovascular disease Prior history of PE, DVT, or stroke. [4]"}
{"id": "article-154122_50", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Estrogen-Containing Contraceptives", "content": "Additionally, estrogen-containing contraceptives are contraindicated in the setting of current or prior history of some hormone-sensitive cancers, especially breast cancer, due to the risk of cancer recurrence or growth stimulation. [40] [28] In the case of ovarian and endometrial cancers, however, the US CDC's Medical Eligibility Criteria state that CHCs are acceptable options while awaiting treatment. [40] Care should be taken in balancing the risks of thromboembolism with the risks of pregnancy while awaiting cancer treatment. [41] [42]", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Estrogen-Containing Contraceptives. Additionally, estrogen-containing contraceptives are contraindicated in the setting of current or prior history of some hormone-sensitive cancers, especially breast cancer, due to the risk of cancer recurrence or growth stimulation. [40] [28] In the case of ovarian and endometrial cancers, however, the US CDC's Medical Eligibility Criteria state that CHCs are acceptable options while awaiting treatment. [40] Care should be taken in balancing the risks of thromboembolism with the risks of pregnancy while awaiting cancer treatment. [41] [42]"}
{"id": "article-154122_51", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Estrogen-Containing Contraceptives", "content": "These methods are also contraindicated in uncontrolled hypertension or known coronary artery disease due to the risk of worsening hypertension and increasing risk for adverse cardiovascular events, respectively. [4] [28] In these clinical settings, patients should be counseled on progesterone-only alternatives, which are safer and equally effective.", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Estrogen-Containing Contraceptives. These methods are also contraindicated in uncontrolled hypertension or known coronary artery disease due to the risk of worsening hypertension and increasing risk for adverse cardiovascular events, respectively. [4] [28] In these clinical settings, patients should be counseled on progesterone-only alternatives, which are safer and equally effective."}
{"id": "article-154122_52", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives", "content": "Progestin-only pills have very few contraindications; the primary absolute contraindication is active breast cancer. Use is also relatively contraindicated in patients with systemic lupus erythematosus (SLE) with antiphospholipid antibodies, severely decompensated cirrhosis, liver tumors, and a history of bariatric surgery with malabsorptive procedures. [40]", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives. Progestin-only pills have very few contraindications; the primary absolute contraindication is active breast cancer. Use is also relatively contraindicated in patients with systemic lupus erythematosus (SLE) with antiphospholipid antibodies, severely decompensated cirrhosis, liver tumors, and a history of bariatric surgery with malabsorptive procedures. [40]"}
{"id": "article-154122_53", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives", "content": "Initiating the levonorgestrel-releasing IUD is contraindicated in the setting of known anatomic abnormalities of the uterus, such as a septate or bicornuate uterus, active genitourinary infection, and current active breast, endometrial, or cervical cancer. [4] [40] [4] Initiating use is also relatively contraindicated in patients with SLE with antiphospholipid antibodies, complicated solid organ transplants, and severely decompensated cirrhosis. [40]", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives. Initiating the levonorgestrel-releasing IUD is contraindicated in the setting of known anatomic abnormalities of the uterus, such as a septate or bicornuate uterus, active genitourinary infection, and current active breast, endometrial, or cervical cancer. [4] [40] [4] Initiating use is also relatively contraindicated in patients with SLE with antiphospholipid antibodies, complicated solid organ transplants, and severely decompensated cirrhosis. [40]"}
{"id": "article-154122_54", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives", "content": "Injectable (and possibly oral) medroxyprogesterone acetate is relatively contraindicated in the setting of known low BMD, known risk factors for BMD loss, or in those with high risk for sequelae of BMD loss. [15] [38] [39] This includes athletes or military personnel with high-volume weight-bearing physical activities, a known history of bone stress injury, athletes with low energy availability, individuals with nutritional deficiency, those in middle age, those with chronic steroid use, or those with immobility. [38] [39]", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives. Injectable (and possibly oral) medroxyprogesterone acetate is relatively contraindicated in the setting of known low BMD, known risk factors for BMD loss, or in those with high risk for sequelae of BMD loss. [15] [38] [39] This includes athletes or military personnel with high-volume weight-bearing physical activities, a known history of bone stress injury, athletes with low energy availability, individuals with nutritional deficiency, those in middle age, those with chronic steroid use, or those with immobility. [38] [39]"}
{"id": "article-154122_55", "title": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives", "content": "It is also relatively contraindicated as a first-line agent in adolescents\u00a0who have not yet reached peak bone mass within\u00a0the first few years after menarche. [23] The ACOG Committee Opinion on medroxyprogesterone acetate and bone effects notes that the rate of BMD accumulation increases significantly at the beginning of puberty but rapidly decreases within the first two years of menarche; they do not make a recommendation regarding age limits\u00a0for DMPA use. [15]", "contents": "Menstrual Suppression -- Contraindications -- Contraindications to Progestin-Only Contraceptives. It is also relatively contraindicated as a first-line agent in adolescents\u00a0who have not yet reached peak bone mass within\u00a0the first few years after menarche. [23] The ACOG Committee Opinion on medroxyprogesterone acetate and bone effects notes that the rate of BMD accumulation increases significantly at the beginning of puberty but rapidly decreases within the first two years of menarche; they do not make a recommendation regarding age limits\u00a0for DMPA use. [15]"}
{"id": "article-154122_56", "title": "Menstrual Suppression -- Contraindications -- Interactions between CHCs/POPs and Anticonvulsant Medication", "content": "Special consideration should be taken when selecting a menstrual suppression method for\u00a0people prescribed anticonvulsant medications due to their known interactions with systemic CHCs and POPs.", "contents": "Menstrual Suppression -- Contraindications -- Interactions between CHCs/POPs and Anticonvulsant Medication. Special consideration should be taken when selecting a menstrual suppression method for\u00a0people prescribed anticonvulsant medications due to their known interactions with systemic CHCs and POPs."}
{"id": "article-154122_57", "title": "Menstrual Suppression -- Contraindications -- Interactions between CHCs/POPs and Anticonvulsant Medication", "content": "Many anticonvulsants and other neuropsychiatric medications (including phenobarbital, phenytoin, carbamazepine, and, to a lesser extent, topiramate) induce the hepatic cytochrome P450 system and interfere with contraceptive efficacy and cycle control reliability. [32] [26] [43] As a result, systemic\u00a0CHCs may result in irregular bleeding, and higher doses may be required to achieve amenorrhea. [43] The CDC Medical Eligibility Criteria for Contraception categorize the estrogen-containing methods and the progesterone-only pill as category 3 (risks outweigh the benefits) for use concurrently with enzyme-inducing anticonvulsant agents. [40]", "contents": "Menstrual Suppression -- Contraindications -- Interactions between CHCs/POPs and Anticonvulsant Medication. Many anticonvulsants and other neuropsychiatric medications (including phenobarbital, phenytoin, carbamazepine, and, to a lesser extent, topiramate) induce the hepatic cytochrome P450 system and interfere with contraceptive efficacy and cycle control reliability. [32] [26] [43] As a result, systemic\u00a0CHCs may result in irregular bleeding, and higher doses may be required to achieve amenorrhea. [43] The CDC Medical Eligibility Criteria for Contraception categorize the estrogen-containing methods and the progesterone-only pill as category 3 (risks outweigh the benefits) for use concurrently with enzyme-inducing anticonvulsant agents. [40]"}
{"id": "article-154122_58", "title": "Menstrual Suppression -- Contraindications -- Interactions between CHCs/POPs and Anticonvulsant Medication", "content": "In general, hormonal contraceptives do not affect the efficacy of anticonvulsant medications, except lamotrigine, which can have decreased efficacy when taken with estrogen. [10] [44] The dose of lamotrigine may need to be adjusted, and a discussion with the prescribing clinician is recommended. [40] [26] Available data is limited but suggests that gabapentin, levetiracetam, and valproate have limited effects on the metabolism of OCPs. [43]", "contents": "Menstrual Suppression -- Contraindications -- Interactions between CHCs/POPs and Anticonvulsant Medication. In general, hormonal contraceptives do not affect the efficacy of anticonvulsant medications, except lamotrigine, which can have decreased efficacy when taken with estrogen. [10] [44] The dose of lamotrigine may need to be adjusted, and a discussion with the prescribing clinician is recommended. [40] [26] Available data is limited but suggests that gabapentin, levetiracetam, and valproate have limited effects on the metabolism of OCPs. [43]"}
{"id": "article-154122_59", "title": "Menstrual Suppression -- Contraindications -- Before Menarche", "content": "Except for care for transgender youth, menstrual suppression should not be initiated before menarche; adolescents must first demonstrate normal anatomy and typical pubertal development. [32] [28]", "contents": "Menstrual Suppression -- Contraindications -- Before Menarche. Except for care for transgender youth, menstrual suppression should not be initiated before menarche; adolescents must first demonstrate normal anatomy and typical pubertal development. [32] [28]"}
{"id": "article-154122_60", "title": "Menstrual Suppression -- Technique or Treatment", "content": "Commonly used hormonal contraceptives may be leveraged to achieve menstrual suppression, including continuous or extended use of the combined OCP, the combined transdermal patch, the combined intravaginal ring, the progestin-only pill, and DMPA, as well as LARC methods such as the levonorgestrel-releasing IUD and the subdermal etonogestrel implant. Less commonly used options include\u00a0GnRH agonists and testosterone.", "contents": "Menstrual Suppression -- Technique or Treatment. Commonly used hormonal contraceptives may be leveraged to achieve menstrual suppression, including continuous or extended use of the combined OCP, the combined transdermal patch, the combined intravaginal ring, the progestin-only pill, and DMPA, as well as LARC methods such as the levonorgestrel-releasing IUD and the subdermal etonogestrel implant. Less commonly used options include\u00a0GnRH agonists and testosterone."}
{"id": "article-154122_61", "title": "Menstrual Suppression -- Technique or Treatment", "content": "Complete cessation of menses is difficult to achieve, and success\u00a0rates and associated side effects vary between methods. Therefore, although complete amenorrhea is possible for some, patients should be counseled on realistic expectations, with the typical goal being to decrease bleeding days and associated burdens. [3] [5]", "contents": "Menstrual Suppression -- Technique or Treatment. Complete cessation of menses is difficult to achieve, and success\u00a0rates and associated side effects vary between methods. Therefore, although complete amenorrhea is possible for some, patients should be counseled on realistic expectations, with the typical goal being to decrease bleeding days and associated burdens. [3] [5]"}
{"id": "article-154122_62", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills", "content": "Continuous or extended use of monophasic combined OCPs is the most well-known method of menstrual suppression among adults and adolescents. Suppression is achieved by taking a daily pill continuously without pausing for a placebo week to precipitate withdrawal bleeding. [3] [12] For example, in a typical pack with 21 active pills and 7 placebo pills, a patient would be instructed to take the 21 active pills and then start the active pills in a new pack on day 22. A\u00a02014 Cochrane Review confirmed that this could be done safely and with similar contraceptive efficacy to 28-day cyclic dosing for an indefinite number of cycles. [3] [12]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills. Continuous or extended use of monophasic combined OCPs is the most well-known method of menstrual suppression among adults and adolescents. Suppression is achieved by taking a daily pill continuously without pausing for a placebo week to precipitate withdrawal bleeding. [3] [12] For example, in a typical pack with 21 active pills and 7 placebo pills, a patient would be instructed to take the 21 active pills and then start the active pills in a new pack on day 22. A\u00a02014 Cochrane Review confirmed that this could be done safely and with similar contraceptive efficacy to 28-day cyclic dosing for an indefinite number of cycles. [3] [12]"}
{"id": "article-154122_63", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills", "content": "Numerous monophasic formulations and brands are available, though they all contain ethinyl estradiol (EE) in combination with a progestin (e.g., norethindrone, levonorgestrel, norgestimate, or drospirenone).\u00a0Different formulations have varying doses of EE combined with different progestins, though, in monophasic formulations, the dose of hormones is the same for each pill in the pack.\u00a0Triphasic formulations are not utilized for menstrual suppression because the varying hormone levels throughout the pack increase the risk of breakthrough bleeding.", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills. Numerous monophasic formulations and brands are available, though they all contain ethinyl estradiol (EE) in combination with a progestin (e.g., norethindrone, levonorgestrel, norgestimate, or drospirenone).\u00a0Different formulations have varying doses of EE combined with different progestins, though, in monophasic formulations, the dose of hormones is the same for each pill in the pack.\u00a0Triphasic formulations are not utilized for menstrual suppression because the varying hormone levels throughout the pack increase the risk of breakthrough bleeding."}
{"id": "article-154122_64", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills", "content": "Higher doses of EE (>20 mcg) are associated with lower rates of bothersome breakthrough bleeding (see Complications ). [3] Higher rates of amenorrhea are reported as the number of cycles of continuous use increases: ~50% report amenorrhea after 2\u00a0or 3 cycles, 69% after 6\u00a0or 7 cycles, and 79 to 88%\u00a0after 12\u00a0or 13 cycles. [45] [46]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills. Higher doses of EE (>20 mcg) are associated with lower rates of bothersome breakthrough bleeding (see Complications ). [3] Higher rates of amenorrhea are reported as the number of cycles of continuous use increases: ~50% report amenorrhea after 2\u00a0or 3 cycles, 69% after 6\u00a0or 7 cycles, and 79 to 88%\u00a0after 12\u00a0or 13 cycles. [45] [46]"}
{"id": "article-154122_65", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills", "content": "Benefits of using OCPs include ease of use, wide accessibility, a large body of data on safety and efficacy, generally high provider knowledge on and comfort with use, and associated improvements in perimenstrual symptoms, including dysmenorrhea, fatigue, bloating, and headache. [45] [12] Additionally, some patients may prefer OCPs to LARC methods due to perceived greater personal control over their cycles and suppression. [5]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills. Benefits of using OCPs include ease of use, wide accessibility, a large body of data on safety and efficacy, generally high provider knowledge on and comfort with use, and associated improvements in perimenstrual symptoms, including dysmenorrhea, fatigue, bloating, and headache. [45] [12] Additionally, some patients may prefer OCPs to LARC methods due to perceived greater personal control over their cycles and suppression. [5]"}
{"id": "article-154122_66", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills", "content": "The downsides include the need for daily patient compliance, the inability to utilize OCPs in patients with contraindications to exogenous estrogen (see Contraindications ), and the risk of breakthrough bleeding, which is of variable annoyance for patients. [3] [12]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Oral Contraceptive Pills. The downsides include the need for daily patient compliance, the inability to utilize OCPs in patients with contraindications to exogenous estrogen (see Contraindications ), and the risk of breakthrough bleeding, which is of variable annoyance for patients. [3] [12]"}
{"id": "article-154122_67", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch", "content": "The transdermal combined contraceptive patch can be used continuously, similarly to OCPs, for menstrual suppression. [3] The patch is replaced weekly with no break week taken to\u00a0precipitate withdrawal bleeding. \"Moderate\" rates of amenorrhea may be achieved; extended use for 12 weeks showed fewer overall bleeding days (6 vs. 14) and fewer breakthrough spotting episodes (2 vs. 3) compared to traditional cyclic use. [47]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch. The transdermal combined contraceptive patch can be used continuously, similarly to OCPs, for menstrual suppression. [3] The patch is replaced weekly with no break week taken to\u00a0precipitate withdrawal bleeding. \"Moderate\" rates of amenorrhea may be achieved; extended use for 12 weeks showed fewer overall bleeding days (6 vs. 14) and fewer breakthrough spotting episodes (2 vs. 3) compared to traditional cyclic use. [47]"}
{"id": "article-154122_68", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch", "content": "The main advantage of this method is weekly rather than daily dosing. Data on prolonged use is limited, as only the EE 75 mcg/norelgestromin 6 mg version of the patch has been studied. [3] [47] Breakthrough bleeding is the most common adverse effect. [3] [47] This method cannot be used in persons with contraindications to exogenous estrogen (see Contraindications ). Intravaginal Ring", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch. The main advantage of this method is weekly rather than daily dosing. Data on prolonged use is limited, as only the EE 75 mcg/norelgestromin 6 mg version of the patch has been studied. [3] [47] Breakthrough bleeding is the most common adverse effect. [3] [47] This method cannot be used in persons with contraindications to exogenous estrogen (see Contraindications ). Intravaginal Ring"}
{"id": "article-154122_69", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch", "content": "Like the patch, the combined intravaginal contraceptive ring can be used continuously for menstrual suppression. The ring is typically replaced every four weeks without a hormone-free interval.\u00a0Only the monthly EE 0.015 mg/etonogestrel 0.120 mg ring has been studied specifically for menstrual suppression. [3]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch. Like the patch, the combined intravaginal contraceptive ring can be used continuously for menstrual suppression. The ring is typically replaced every four weeks without a hormone-free interval.\u00a0Only the monthly EE 0.015 mg/etonogestrel 0.120 mg ring has been studied specifically for menstrual suppression. [3]"}
{"id": "article-154122_70", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch", "content": "This method demonstrates \"excellent\" amenorrhea rates: a 2008 study demonstrated up to 89% of users had no to minimal bleeding at six months of continuous use. [48] [3] Some evidence suggests that vaginal administration may result in more stable serum estrogen and progesterone concentrations than the patch or OCPs. [4] [49] Monthly rather than weekly or daily dosing may be advantageous for compliance and convenience and increase patients' perceived control over their menses. [5]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch. This method demonstrates \"excellent\" amenorrhea rates: a 2008 study demonstrated up to 89% of users had no to minimal bleeding at six months of continuous use. [48] [3] Some evidence suggests that vaginal administration may result in more stable serum estrogen and progesterone concentrations than the patch or OCPs. [4] [49] Monthly rather than weekly or daily dosing may be advantageous for compliance and convenience and increase patients' perceived control over their menses. [5]"}
{"id": "article-154122_71", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch", "content": "The\u00a0most significant downside and common reason for discontinuing the ring is bothersome breakthrough bleeding. Although full menstrual-type bleeding days decrease with extended ring use, spotting days may increase compared to cyclic use. [49] [3] However, there is evidence to suggest that if bothersome spotting occurs for more than\u00a05 days, this issue may improve with an on-demand 4-day hormone-free interval. [48] The ring can then be replaced, and continuous use resumed. [48] [3]", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch. The\u00a0most significant downside and common reason for discontinuing the ring is bothersome breakthrough bleeding. Although full menstrual-type bleeding days decrease with extended ring use, spotting days may increase compared to cyclic use. [49] [3] However, there is evidence to suggest that if bothersome spotting occurs for more than\u00a05 days, this issue may improve with an on-demand 4-day hormone-free interval. [48] The ring can then be replaced, and continuous use resumed. [48] [3]"}
{"id": "article-154122_72", "title": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch", "content": "Another disadvantage is the requirement for refrigeration of the rings if they are to be stored by the patient longer than four months, which may create a barrier for those who do not have access to reliable refrigeration or electricity. The newer EE 17.4 mg/segesterone acetate 103 mg ring is a longer-acting effective contraceptive that can remain in place for 12 months and does not require refrigeration or repeat prescriptions. However, data is limited regarding rates of amenorrhea achieved with continuous use of this method, and more research is necessary to understand its efficacy for menstrual suppression. [3] This method cannot be used in persons with contraindications to exogenous estrogen (see Contraindications ).", "contents": "Menstrual Suppression -- Technique or Treatment -- Combined Transdermal Patch. Another disadvantage is the requirement for refrigeration of the rings if they are to be stored by the patient longer than four months, which may create a barrier for those who do not have access to reliable refrigeration or electricity. The newer EE 17.4 mg/segesterone acetate 103 mg ring is a longer-acting effective contraceptive that can remain in place for 12 months and does not require refrigeration or repeat prescriptions. However, data is limited regarding rates of amenorrhea achieved with continuous use of this method, and more research is necessary to understand its efficacy for menstrual suppression. [3] This method cannot be used in persons with contraindications to exogenous estrogen (see Contraindications )."}
{"id": "article-154122_73", "title": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills", "content": "Oral progestin-only pills (POPs), including norethindrone, norethindrone acetate, and drospirenone, may be used for menstrual suppression, particularly in persons with contraindications to exogenous estrogen. [3] The use of oral medroxyprogesterone acetate (up to 20 mg daily in divided doses) has also been described. Outside the United States, other progestins may be available as POPs, including desogestrel and norgestrel.\u00a0Note that norethindrone and norethindrone acetate are different compounds, and only norethindrone (0.35 mg) and drospirenone (4 mg) have been approved as contraceptives in the U.S. [50]", "contents": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills. Oral progestin-only pills (POPs), including norethindrone, norethindrone acetate, and drospirenone, may be used for menstrual suppression, particularly in persons with contraindications to exogenous estrogen. [3] The use of oral medroxyprogesterone acetate (up to 20 mg daily in divided doses) has also been described. Outside the United States, other progestins may be available as POPs, including desogestrel and norgestrel.\u00a0Note that norethindrone and norethindrone acetate are different compounds, and only norethindrone (0.35 mg) and drospirenone (4 mg) have been approved as contraceptives in the U.S. [50]"}
{"id": "article-154122_74", "title": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills", "content": "Amenorrhea has been reported in up to 76% of users at two years with standard doses of norethindrone acetate (5 mg). However, rates are as low as 10% with standard doses of norethindrone (0.35 mg), and data on rates with drospirenone (4 mg) are limited. [3] [50] [28] [50]", "contents": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills. Amenorrhea has been reported in up to 76% of users at two years with standard doses of norethindrone acetate (5 mg). However, rates are as low as 10% with standard doses of norethindrone (0.35 mg), and data on rates with drospirenone (4 mg) are limited. [3] [50] [28] [50]"}
{"id": "article-154122_75", "title": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills", "content": "The main advantages of progestin-only pills are the ability to use them in individuals with contraindications to exogenous estrogen, the ability to adjust the dose and frequency easily, and the ease of use and start. [3] [40]", "contents": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills. The main advantages of progestin-only pills are the ability to use them in individuals with contraindications to exogenous estrogen, the ability to adjust the dose and frequency easily, and the ease of use and start. [3] [40]"}
{"id": "article-154122_76", "title": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills", "content": "However, the disadvantages are significant, including low and inconsistent rates of amenorrhea, higher prices compared to combined OCPs, the need for strict adherence and timed daily dosing for adequate suppression and contraceptive efficacy, and irregular breakthrough bleeding. [32] [3] Progestin-only pills are not typically recommended for use in adolescents. [23]", "contents": "Menstrual Suppression -- Technique or Treatment -- Progestin-only Oral Pills. However, the disadvantages are significant, including low and inconsistent rates of amenorrhea, higher prices compared to combined OCPs, the need for strict adherence and timed daily dosing for adequate suppression and contraceptive efficacy, and irregular breakthrough bleeding. [32] [3] Progestin-only pills are not typically recommended for use in adolescents. [23]"}
{"id": "article-154122_77", "title": "Menstrual Suppression -- Technique or Treatment -- Injectable Depot Medroxyprogesterone Acetate (DMPA)", "content": "DMPA\u00a0is a longer-acting contraceptive option that may be leveraged for menstrual suppression; it is injected either intramuscularly at a dose of 150 mg or subcutaneously at a dose of 104 mg every 11 to 13 weeks. [3] Amenorrhea rates are as high as 71% at two years and increase with prolonged use. [4] [3]", "contents": "Menstrual Suppression -- Technique or Treatment -- Injectable Depot Medroxyprogesterone Acetate (DMPA). DMPA\u00a0is a longer-acting contraceptive option that may be leveraged for menstrual suppression; it is injected either intramuscularly at a dose of 150 mg or subcutaneously at a dose of 104 mg every 11 to 13 weeks. [3] Amenorrhea rates are as high as 71% at two years and increase with prolonged use. [4] [3]"}
{"id": "article-154122_78", "title": "Menstrual Suppression -- Technique or Treatment -- Injectable Depot Medroxyprogesterone Acetate (DMPA)", "content": "Advantages include infrequent dosing, ease of administration, and high amenorrhea rates. [4] [3] DMPA is a commonly used menstrual suppression method among young women with developmental or physical disabilities, though it must be used with caution due to its effect on bone health (see Complications ). [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- Injectable Depot Medroxyprogesterone Acetate (DMPA). Advantages include infrequent dosing, ease of administration, and high amenorrhea rates. [4] [3] DMPA is a commonly used menstrual suppression method among young women with developmental or physical disabilities, though it must be used with caution due to its effect on bone health (see Complications ). [32]"}
{"id": "article-154122_79", "title": "Menstrual Suppression -- Technique or Treatment -- Injectable Depot Medroxyprogesterone Acetate (DMPA)", "content": "Disadvantages\u00a0include initial excessive prolonged uterine bleeding with the first dose as the existing endometrial lining is shed, the need for an in-person clinic visit for repeated injections four or more times per year, weight gain associated with high-dose progesterone, and loss of BMD (see Complications ). [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- Injectable Depot Medroxyprogesterone Acetate (DMPA). Disadvantages\u00a0include initial excessive prolonged uterine bleeding with the first dose as the existing endometrial lining is shed, the need for an in-person clinic visit for repeated injections four or more times per year, weight gain associated with high-dose progesterone, and loss of BMD (see Complications ). [32]"}
{"id": "article-154122_80", "title": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device", "content": "The levonorgestrel-releasing IUDs (52 mg, 19.5 mg, or 13.5 mg) are progestin-only LARC methods that can effectively achieve menstrual suppression. The 52 mg device demonstrates the highest rates of amenorrhea: up to 50% of users will be amenorrhoeic at 6 to 12 months, and\u00a0up to 60% will be amenorrhoeic at five years. [4] [3] [32] Since the lower dose devices have lower amenorrhea rates, the 52-mg device is preferred for the indication of menstrual suppression. [3]", "contents": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device. The levonorgestrel-releasing IUDs (52 mg, 19.5 mg, or 13.5 mg) are progestin-only LARC methods that can effectively achieve menstrual suppression. The 52 mg device demonstrates the highest rates of amenorrhea: up to 50% of users will be amenorrhoeic at 6 to 12 months, and\u00a0up to 60% will be amenorrhoeic at five years. [4] [3] [32] Since the lower dose devices have lower amenorrhea rates, the 52-mg device is preferred for the indication of menstrual suppression. [3]"}
{"id": "article-154122_81", "title": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device", "content": "The devices are used for 3 to 8 years at a time, with the duration depending on device dose and brand; the 52-mg device is approved for contraception for up to 8 years, and menstrual suppression rates appear to remain high throughout that time.", "contents": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device. The devices are used for 3 to 8 years at a time, with the duration depending on device dose and brand; the 52-mg device is approved for contraception for up to 8 years, and menstrual suppression rates appear to remain high throughout that time."}
{"id": "article-154122_82", "title": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device", "content": "Benefits of using the levonorgestrel-releasing IUD include excellent contraceptive efficacy (<0.2% failure rate), lower volume of menstrual blood loss,\u00a0long\u00a0duration of the use for a single device, reliable compliance (no individual user variability), ability to utilize the device in individuals with contraindications to exogenous estrogen, and treatment benefits for other medical conditions such as heavy menstrual bleeding, endometriosis, adenomyosis, leiomyomas, and hemostatic disorders. [40] [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device. Benefits of using the levonorgestrel-releasing IUD include excellent contraceptive efficacy (<0.2% failure rate), lower volume of menstrual blood loss,\u00a0long\u00a0duration of the use for a single device, reliable compliance (no individual user variability), ability to utilize the device in individuals with contraindications to exogenous estrogen, and treatment benefits for other medical conditions such as heavy menstrual bleeding, endometriosis, adenomyosis, leiomyomas, and hemostatic disorders. [40] [32]"}
{"id": "article-154122_83", "title": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device", "content": "Disadvantages include insertion-related pain and fear, the need for a provider trained in the placement procedure, difficulty accessing the procedure, lack of provider knowledge, up-front expense, breakthrough bleeding, and the potential for mechanical complications and expulsion (see Complications ). [3] [32] Breakthrough bleeding is most likely during the initial 3 to 6 months after placement and improves with time; as few as 11% of users will experience spotting at two years. [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device. Disadvantages include insertion-related pain and fear, the need for a provider trained in the placement procedure, difficulty accessing the procedure, lack of provider knowledge, up-front expense, breakthrough bleeding, and the potential for mechanical complications and expulsion (see Complications ). [3] [32] Breakthrough bleeding is most likely during the initial 3 to 6 months after placement and improves with time; as few as 11% of users will experience spotting at two years. [32]"}
{"id": "article-154122_84", "title": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device", "content": "The levonorgestrel-releasing IUD can be safely used for menstrual suppression in adolescents, and ACOG supports its use in this population. [51] [23] Prior concerns that placement in nulligravid adolescents would be impossible or lead to higher rates of expulsion or uterine perforation have not been founded. The risk of expulsion is low at 8%, and the risk of perforation is documented as low as 0%. [23]", "contents": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device. The levonorgestrel-releasing IUD can be safely used for menstrual suppression in adolescents, and ACOG supports its use in this population. [51] [23] Prior concerns that placement in nulligravid adolescents would be impossible or lead to higher rates of expulsion or uterine perforation have not been founded. The risk of expulsion is low at 8%, and the risk of perforation is documented as low as 0%. [23]"}
{"id": "article-154122_85", "title": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device", "content": "There are many misunderstandings and fears regarding the IUD that decrease its popularity for menstrual suppression and contraception in general, including perceived lack of personal control over menses, fear of pain or complications associated with placement, fear of having a foreign object inside the body, and fear that not having a predictable period will decrease personal certainty that pregnancy has not occurred. [5] Appropriate counseling can help alleviate some of these fears. However, clinicians must not dismiss patient concerns or make patients feel coerced. [3] The copper-containing IUD is inappropriate for menstrual suppression, as it does not alter menstrual cycle physiology or the endometrial lining. [4] [40]", "contents": "Menstrual Suppression -- Technique or Treatment -- Levonorgestrel-releasing Intrauterine Device. There are many misunderstandings and fears regarding the IUD that decrease its popularity for menstrual suppression and contraception in general, including perceived lack of personal control over menses, fear of pain or complications associated with placement, fear of having a foreign object inside the body, and fear that not having a predictable period will decrease personal certainty that pregnancy has not occurred. [5] Appropriate counseling can help alleviate some of these fears. However, clinicians must not dismiss patient concerns or make patients feel coerced. [3] The copper-containing IUD is inappropriate for menstrual suppression, as it does not alter menstrual cycle physiology or the endometrial lining. [4] [40]"}
{"id": "article-154122_86", "title": "Menstrual Suppression -- Technique or Treatment -- Subdermal Etonogestrel Implant", "content": "The subdermal etonogestrel-containing implant is an extremely effective contraceptive device (<0.05% failure rate) and an additional method to consider for menstrual suppression. [40] However, amenorrhea rates are inconsistent and reported to be as low as 13% to 22% at 12 months, and the risks of menstrual irregularity and breakthrough bleeding are high. [32] [3]", "contents": "Menstrual Suppression -- Technique or Treatment -- Subdermal Etonogestrel Implant. The subdermal etonogestrel-containing implant is an extremely effective contraceptive device (<0.05% failure rate) and an additional method to consider for menstrual suppression. [40] However, amenorrhea rates are inconsistent and reported to be as low as 13% to 22% at 12 months, and the risks of menstrual irregularity and breakthrough bleeding are high. [32] [3]"}
{"id": "article-154122_87", "title": "Menstrual Suppression -- Technique or Treatment -- Subdermal Etonogestrel Implant", "content": "It is not typically recommended for menstrual suppression in adolescents because up to 22% of adolescent users request removal for breakthrough bleeding. [23] The high upfront cost and insertion-related pain should also be considered. [3]", "contents": "Menstrual Suppression -- Technique or Treatment -- Subdermal Etonogestrel Implant. It is not typically recommended for menstrual suppression in adolescents because up to 22% of adolescent users request removal for breakthrough bleeding. [23] The high upfront cost and insertion-related pain should also be considered. [3]"}
{"id": "article-154122_88", "title": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists", "content": "GnRH agonists are non-contraceptive\u00a0medications that may be utilized for menstrual suppression by creating a hypoestrogenic state. [3] [32] Although somewhat counterintuitive, the continuous presence of GnRH inhibits the release of FSH and LH (these hormones typically respond to intermittent GnRH pulses).", "contents": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists. GnRH agonists are non-contraceptive\u00a0medications that may be utilized for menstrual suppression by creating a hypoestrogenic state. [3] [32] Although somewhat counterintuitive, the continuous presence of GnRH inhibits the release of FSH and LH (these hormones typically respond to intermittent GnRH pulses)."}
{"id": "article-154122_89", "title": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists", "content": "The most common formulation is depot-leuprolide acetate 11.25 mg IM injection given every 12 weeks, though it may also be given once\u00a0monthly at a dose of 3.75 mg IM or via subdermal implant or intranasally at varying doses. [3] [32] Triptorelin may also be utilized.", "contents": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists. The most common formulation is depot-leuprolide acetate 11.25 mg IM injection given every 12 weeks, though it may also be given once\u00a0monthly at a dose of 3.75 mg IM or via subdermal implant or intranasally at varying doses. [3] [32] Triptorelin may also be utilized."}
{"id": "article-154122_90", "title": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists", "content": "GnRH agonists are\u00a0utilized in transgender and gender-diverse adolescents for delay or blockade of puberty in support of gender-affirming care, in individuals with malignancy, or in individuals with endometriosis or severe heavy menstrual bleeding with anemia which is refractory to other hormonal treatments. [3] [32] [23] Rates of amenorrhea are as high as 96%. [32] [42] [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists. GnRH agonists are\u00a0utilized in transgender and gender-diverse adolescents for delay or blockade of puberty in support of gender-affirming care, in individuals with malignancy, or in individuals with endometriosis or severe heavy menstrual bleeding with anemia which is refractory to other hormonal treatments. [3] [32] [23] Rates of amenorrhea are as high as 96%. [32] [42] [32]"}
{"id": "article-154122_91", "title": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists", "content": "However, several significant disadvantages are associated with the hypoestrogenic state induced by GnRH agonists, including perimenopausal symptoms and a decrease in BMD (see Complications ). [3] [23] [32] Patients should also be counseled to expect an initial \"flare\" in bleeding within 1\u00a0to 3 weeks until hormone levels are adequately suppressed. [42]", "contents": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists. However, several significant disadvantages are associated with the hypoestrogenic state induced by GnRH agonists, including perimenopausal symptoms and a decrease in BMD (see Complications ). [3] [23] [32] Patients should also be counseled to expect an initial \"flare\" in bleeding within 1\u00a0to 3 weeks until hormone levels are adequately suppressed. [42]"}
{"id": "article-154122_92", "title": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists", "content": "Additionally, GnRH agonists are very expensive, ineffective as a form of contraception, and may be less accessible in the primary care setting due to lower provider familiarity. [3] The recommendation is that GnRH agonists not be used for a prolonged period due to risks of BMD loss; add-back therapy  (such as norethindrone acetate 5 mg once daily) can help reduce this risk and minimize other bothersome symptoms. [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- GnRH Agonists. Additionally, GnRH agonists are very expensive, ineffective as a form of contraception, and may be less accessible in the primary care setting due to lower provider familiarity. [3] The recommendation is that GnRH agonists not be used for a prolonged period due to risks of BMD loss; add-back therapy  (such as norethindrone acetate 5 mg once daily) can help reduce this risk and minimize other bothersome symptoms. [32]"}
{"id": "article-154122_93", "title": "Menstrual Suppression -- Technique or Treatment -- Testosterone", "content": "Among transgender and gender-diverse persons, testosterone can be used for menstrual suppression. Testosterone acts directly on the endometrium, causing atrophy. [52]", "contents": "Menstrual Suppression -- Technique or Treatment -- Testosterone. Among transgender and gender-diverse persons, testosterone can be used for menstrual suppression. Testosterone acts directly on the endometrium, causing atrophy. [52]"}
{"id": "article-154122_94", "title": "Menstrual Suppression -- Technique or Treatment -- Testosterone", "content": "Testosterone can be administered via topical gel, subcutaneous injection, or intramuscular injection. Intramuscular injection is the most common with testosterone enanthate or cypionate. A typical starting dose of both formulations is 100 mg every two weeks intramuscularly. [35]  Amenorrhea is achieved in a\u00a0dose-dependent response to testosterone, with higher or more frequent doses achieving amenorrhea sooner. [53] Across formulations, amenorrhea is typically achieved within six months. [32] [53] [54] It is important to note that testosterone is not an adequate contraceptive method, and pregnancy has been reported while actively using testosterone. [37] [32]", "contents": "Menstrual Suppression -- Technique or Treatment -- Testosterone. Testosterone can be administered via topical gel, subcutaneous injection, or intramuscular injection. Intramuscular injection is the most common with testosterone enanthate or cypionate. A typical starting dose of both formulations is 100 mg every two weeks intramuscularly. [35]  Amenorrhea is achieved in a\u00a0dose-dependent response to testosterone, with higher or more frequent doses achieving amenorrhea sooner. [53] Across formulations, amenorrhea is typically achieved within six months. [32] [53] [54] It is important to note that testosterone is not an adequate contraceptive method, and pregnancy has been reported while actively using testosterone. [37] [32]"}
{"id": "article-154122_95", "title": "Menstrual Suppression -- Complications -- Breakthrough Bleeding", "content": "The most common adverse effect of menstrual suppression in all patient populations is breakthrough bleeding (BTB) at unexpected times. This bleeding is benign, though it can be distressing or inconvenient and is a common reason for treatment discontinuation. [3] Up to 46% of\u00a0individuals\u00a0may experience\u00a0BTB across methods, most commonly with the subdermal etonogestrel implant and progestin-only pills. [3] [32]", "contents": "Menstrual Suppression -- Complications -- Breakthrough Bleeding. The most common adverse effect of menstrual suppression in all patient populations is breakthrough bleeding (BTB) at unexpected times. This bleeding is benign, though it can be distressing or inconvenient and is a common reason for treatment discontinuation. [3] Up to 46% of\u00a0individuals\u00a0may experience\u00a0BTB across methods, most commonly with the subdermal etonogestrel implant and progestin-only pills. [3] [32]"}
{"id": "article-154122_96", "title": "Menstrual Suppression -- Complications -- Breakthrough Bleeding", "content": "All patients should be counseled regarding the expectation for possible benign breakthrough bleeding and that rates decrease with a longer duration of continuous hormonal contraceptive use, particularly if used longer than six months. [3] Several strategies per method are offered by the ACOG 2022 Clinical Consensus on menstrual suppression for the management of BTB. When BTB\u00a0occurs while using CHCs , including OCPs, patches, or rings, clinicians can consider the following: Consider cyclic cycles for 3 to 6 months, then transition to extended cycles (e.g., use CHCs for 12 weeks, followed by a 4\u00a0to 7-day hormone-free interval) Completing a 3-4-day hormone-free interval Intermittent supplementation with estrogen. [3] [48] [12] When\u00a0BTB occurs while using POPs , clinicians can consider the following:", "contents": "Menstrual Suppression -- Complications -- Breakthrough Bleeding. All patients should be counseled regarding the expectation for possible benign breakthrough bleeding and that rates decrease with a longer duration of continuous hormonal contraceptive use, particularly if used longer than six months. [3] Several strategies per method are offered by the ACOG 2022 Clinical Consensus on menstrual suppression for the management of BTB. When BTB\u00a0occurs while using CHCs , including OCPs, patches, or rings, clinicians can consider the following: Consider cyclic cycles for 3 to 6 months, then transition to extended cycles (e.g., use CHCs for 12 weeks, followed by a 4\u00a0to 7-day hormone-free interval) Completing a 3-4-day hormone-free interval Intermittent supplementation with estrogen. [3] [48] [12] When\u00a0BTB occurs while using POPs , clinicians can consider the following:"}
{"id": "article-154122_97", "title": "Menstrual Suppression -- Complications -- Breakthrough Bleeding", "content": "Counseling that breakthrough bleeding may decrease with consistent daily dose timing (e.g., taking the dose at the same time each day) Increasing the dose Completing a brief dose taper of norethindrone (increase to 0.7 mg for 7 days, then returning to normal 0.35 mg dose). [3] When BTB occurs while using DMPA or\u00a0the etonogestrel implant , clinicians can consider the following: Use of combined OCPs or oral estrogen alone for 10 to 20 days A course of non-steroidal anti-inflammatory drugs (NSAIDs) for up to 7 days Increasing injection frequency of\u00a0DMPA to rapidly achieve amenorrhea (up to every 4 to 6 weeks for 2 to 3 doses), then consider returning to regular dosing. [3] [4] When\u00a0BTB occurs while using levonorgestrel-releasing IUD , clinicians can consider the following:", "contents": "Menstrual Suppression -- Complications -- Breakthrough Bleeding. Counseling that breakthrough bleeding may decrease with consistent daily dose timing (e.g., taking the dose at the same time each day) Increasing the dose Completing a brief dose taper of norethindrone (increase to 0.7 mg for 7 days, then returning to normal 0.35 mg dose). [3] When BTB occurs while using DMPA or\u00a0the etonogestrel implant , clinicians can consider the following: Use of combined OCPs or oral estrogen alone for 10 to 20 days A course of non-steroidal anti-inflammatory drugs (NSAIDs) for up to 7 days Increasing injection frequency of\u00a0DMPA to rapidly achieve amenorrhea (up to every 4 to 6 weeks for 2 to 3 doses), then consider returning to regular dosing. [3] [4] When\u00a0BTB occurs while using levonorgestrel-releasing IUD , clinicians can consider the following:"}
{"id": "article-154122_98", "title": "Menstrual Suppression -- Complications -- Breakthrough Bleeding", "content": "Preferential use of the higher dose device (52 mg levonorgestrel) A brief course of combined OCPs or progestin-only pills, scheduled NSAIDs, or oral sub-antimicrobial-dose doxycycline Watchful waiting for up to 6 months Counsel patients on alternative methods [3]", "contents": "Menstrual Suppression -- Complications -- Breakthrough Bleeding. Preferential use of the higher dose device (52 mg levonorgestrel) A brief course of combined OCPs or progestin-only pills, scheduled NSAIDs, or oral sub-antimicrobial-dose doxycycline Watchful waiting for up to 6 months Counsel patients on alternative methods [3]"}
{"id": "article-154122_99", "title": "Menstrual Suppression -- Complications -- Complications Related to Estrogen", "content": "Complications specific to estrogen-containing methods include thromboembolism (DVT, PE, stroke), new or worsening of prior hypertension, cardiac events\u00a0when used in patients with cardiovascular disease, and hepatic hemangioma. [4] [40] These risks are similarly present in the special populations discussed.", "contents": "Menstrual Suppression -- Complications -- Complications Related to Estrogen. Complications specific to estrogen-containing methods include thromboembolism (DVT, PE, stroke), new or worsening of prior hypertension, cardiac events\u00a0when used in patients with cardiovascular disease, and hepatic hemangioma. [4] [40] These risks are similarly present in the special populations discussed."}
{"id": "article-154122_100", "title": "Menstrual Suppression -- Complications -- Complications Related to Estrogen", "content": "Previously, concerns were raised regarding cancer risk associated with the long-term use of OCPs. However, a 2017 study of over 46,000 women demonstrated a decreased risk of colorectal, endometrial, ovarian, and hematological cancers in those with OCP use within their lifetime. [16] The study also showed that any increased risk of breast and cervical cancer seen initially in OCP users resolves within five years of discontinuation.", "contents": "Menstrual Suppression -- Complications -- Complications Related to Estrogen. Previously, concerns were raised regarding cancer risk associated with the long-term use of OCPs. However, a 2017 study of over 46,000 women demonstrated a decreased risk of colorectal, endometrial, ovarian, and hematological cancers in those with OCP use within their lifetime. [16] The study also showed that any increased risk of breast and cervical cancer seen initially in OCP users resolves within five years of discontinuation."}
{"id": "article-154122_101", "title": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins", "content": "Injectable (and possibly oral) medroxyprogesterone acetate is associated with decreased BMD when used for two years or longer, though this loss is largely reversible. [15] [32] [4] [23] Elevated\u00a0levels of biomarkers for bone formation and resorption and lower average BMD have been seen in long-term users compared to non-users. [4] BMD loss increases with the increasing duration of\u00a0DMPA use, at least two years, with studies showing BMD loss at the hip and spine of 0.5 to 3.5% at one year and up to 7.5% at two years. [15] Complete recovery of BMD loss is\u00a0highly likely if DMPA is used for < 2 years. [3] [32] [23]", "contents": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins. Injectable (and possibly oral) medroxyprogesterone acetate is associated with decreased BMD when used for two years or longer, though this loss is largely reversible. [15] [32] [4] [23] Elevated\u00a0levels of biomarkers for bone formation and resorption and lower average BMD have been seen in long-term users compared to non-users. [4] BMD loss increases with the increasing duration of\u00a0DMPA use, at least two years, with studies showing BMD loss at the hip and spine of 0.5 to 3.5% at one year and up to 7.5% at two years. [15] Complete recovery of BMD loss is\u00a0highly likely if DMPA is used for < 2 years. [3] [32] [23]"}
{"id": "article-154122_102", "title": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins", "content": "However, BMD loss may level out beyond that, with\u00a0a significant portion of the loss being reversible. One prospective cohort study of 248 new DMPA users showed a BMD loss of only 5.4% compared to\u00a0their baseline after five years of use. [55] This same study showed substantial BMD recovery within two years of discontinuation, with\u00a0BMD\u00a0only 1.2% below\u00a0their original by 96 weeks posttreatment. [23]", "contents": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins. However, BMD loss may level out beyond that, with\u00a0a significant portion of the loss being reversible. One prospective cohort study of 248 new DMPA users showed a BMD loss of only 5.4% compared to\u00a0their baseline after five years of use. [55] This same study showed substantial BMD recovery within two years of discontinuation, with\u00a0BMD\u00a0only 1.2% below\u00a0their original by 96 weeks posttreatment. [23]"}
{"id": "article-154122_103", "title": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins", "content": "The main concern with this effect is the possibility of a higher risk of osteoporosis, bone stress injury, or fulminant fracture. This may be of particular concern among individuals who already carry these risks for other reasons, such as athletes or military personnel with high-volume weight-bearing physical activities, athletes with low energy availability, individuals with nutritional deficiency, those in middle age, those with chronic steroid use, or those with immobility. [38] [39] There is no high-quality data regarding fracture risk later in life in DMPA users. [15] Some evidence suggests that age-appropriate supplemental calcium (1200 mg daily) and vitamin D may decrease BMD loss for adolescents if taken\u00a0concurrently with DMPA. [23]", "contents": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins. The main concern with this effect is the possibility of a higher risk of osteoporosis, bone stress injury, or fulminant fracture. This may be of particular concern among individuals who already carry these risks for other reasons, such as athletes or military personnel with high-volume weight-bearing physical activities, athletes with low energy availability, individuals with nutritional deficiency, those in middle age, those with chronic steroid use, or those with immobility. [38] [39] There is no high-quality data regarding fracture risk later in life in DMPA users. [15] Some evidence suggests that age-appropriate supplemental calcium (1200 mg daily) and vitamin D may decrease BMD loss for adolescents if taken\u00a0concurrently with DMPA. [23]"}
{"id": "article-154122_104", "title": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins", "content": "Despite the concern for BMD loss, the benefits of preventing pregnancy or suppressing menses may outweigh this risk, even in adolescents. There is no recommendation from ACOG or AAP on limiting the duration of use to 2 years. [23] Patients should be counseled on the risks and benefits so they may make the most informed decision for themselves. [23]", "contents": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins. Despite the concern for BMD loss, the benefits of preventing pregnancy or suppressing menses may outweigh this risk, even in adolescents. There is no recommendation from ACOG or AAP on limiting the duration of use to 2 years. [23] Patients should be counseled on the risks and benefits so they may make the most informed decision for themselves. [23]"}
{"id": "article-154122_105", "title": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins", "content": "The etonogestrel implant and LNG-IUD\u00a0are not associated with\u00a0BMD loss. Additionally, in general, progestins do not have any strong evidence to suggest an increased risk of breast cancer, cardiovascular disease, or thromboembolism.", "contents": "Menstrual Suppression -- Complications -- Complications Related to\u00a0Progestins. The etonogestrel implant and LNG-IUD\u00a0are not associated with\u00a0BMD loss. Additionally, in general, progestins do not have any strong evidence to suggest an increased risk of breast cancer, cardiovascular disease, or thromboembolism."}
{"id": "article-154122_106", "title": "Menstrual Suppression -- Complications -- Complications Related to\u00a0GnRH Agonists", "content": "Adverse effects specific to GnRH agonists stem from the induction of a hypoestrogenic state. These include BMD loss, the risk for cardiovascular disease, headache, and menopausal symptoms such as hot flashes, mood changes, and fatigue. [3] [23] [32]", "contents": "Menstrual Suppression -- Complications -- Complications Related to\u00a0GnRH Agonists. Adverse effects specific to GnRH agonists stem from the induction of a hypoestrogenic state. These include BMD loss, the risk for cardiovascular disease, headache, and menopausal symptoms such as hot flashes, mood changes, and fatigue. [3] [23] [32]"}
{"id": "article-154122_107", "title": "Menstrual Suppression -- Complications -- Impact on Fertility", "content": "One of the common fears associated with menstrual suppression and hormonal contraception, in general, is the fear of alteration in baseline fertility after use.\u00a0Baseline fertility rates do not appear to be affected for any of the methods beyond normal age-related fertility decline.", "contents": "Menstrual Suppression -- Complications -- Impact on Fertility. One of the common fears associated with menstrual suppression and hormonal contraception, in general, is the fear of alteration in baseline fertility after use.\u00a0Baseline fertility rates do not appear to be affected for any of the methods beyond normal age-related fertility decline."}
{"id": "article-154122_108", "title": "Menstrual Suppression -- Complications -- Impact on Fertility", "content": "There may, however, be a delay in the resumption of ovulation and normal menses, depending on the method and duration of use. For this reason, within the first several months of discontinuing hormonal contraception, fertility rates in people using hormonal menstrual suppression methods may be lower than fertility rates in non-users. This initial delay is more likely seen in DMPA and CHC users than IUD users. However, there is no significant difference in pregnancy rates between methods by one year after stopping the method. [56] Additionally, after 12 months of attempting conception, the overall birth rate in patients using\u00a0menstrual suppression methods\u00a0appears comparable to the general population. [56]", "contents": "Menstrual Suppression -- Complications -- Impact on Fertility. There may, however, be a delay in the resumption of ovulation and normal menses, depending on the method and duration of use. For this reason, within the first several months of discontinuing hormonal contraception, fertility rates in people using hormonal menstrual suppression methods may be lower than fertility rates in non-users. This initial delay is more likely seen in DMPA and CHC users than IUD users. However, there is no significant difference in pregnancy rates between methods by one year after stopping the method. [56] Additionally, after 12 months of attempting conception, the overall birth rate in patients using\u00a0menstrual suppression methods\u00a0appears comparable to the general population. [56]"}
{"id": "article-154122_109", "title": "Menstrual Suppression -- Clinical Significance", "content": "Up to 26% of the global population menstruates. [1] As discussed in Indications , 800 million people menstruate on any given day, and bothersome menstrual-related symptoms (heavy menstrual bleeding, dysmenorrhea, premenstrual syndrome, bloating, fatigue) impact up to 2.5 million\u00a0people\u00a0annually. [1] [4]", "contents": "Menstrual Suppression -- Clinical Significance. Up to 26% of the global population menstruates. [1] As discussed in Indications , 800 million people menstruate on any given day, and bothersome menstrual-related symptoms (heavy menstrual bleeding, dysmenorrhea, premenstrual syndrome, bloating, fatigue) impact up to 2.5 million\u00a0people\u00a0annually. [1] [4]"}
{"id": "article-154122_110", "title": "Menstrual Suppression -- Clinical Significance", "content": "Negative symptoms associated with menses may lead to absenteeism from school or work, resulting in loss of education and income, decreased participation in social, athletic, professional, or recreational activities, embarrassment or social ostracization, excessive income spent on menstrual hygiene products like pads, tampons, menstrual cups, and panties, increased risk for genitourinary infections, and excessive blood loss and associated anemia. These consequences may disproportionately impact those living in poverty, adolescents, persons with developmental or physical disabilities, gender-diverse persons, military personnel, athletes, and persons with malignancy (see discussion of \"period poverty\"\u00a0and \"Special Populations\" in Indications ).", "contents": "Menstrual Suppression -- Clinical Significance. Negative symptoms associated with menses may lead to absenteeism from school or work, resulting in loss of education and income, decreased participation in social, athletic, professional, or recreational activities, embarrassment or social ostracization, excessive income spent on menstrual hygiene products like pads, tampons, menstrual cups, and panties, increased risk for genitourinary infections, and excessive blood loss and associated anemia. These consequences may disproportionately impact those living in poverty, adolescents, persons with developmental or physical disabilities, gender-diverse persons, military personnel, athletes, and persons with malignancy (see discussion of \"period poverty\"\u00a0and \"Special Populations\" in Indications )."}
{"id": "article-154122_111", "title": "Menstrual Suppression -- Clinical Significance", "content": "By utilizing menstrual suppression methods, amenorrhea or oligomenorrhea may be achieved, and the described negative impacts of menses may be mitigated\u00a0(see discussion of the impact on special populations in Indications ). Rates of amenorrhea per method are as follows: OCPs: 88% by 12 months POPs: widely variable depending on formulation and dose, 10\u00a0to 76% DMPA: up to 71% by\u00a02 years Levonorgestrel-releasing IUD: 50% by 12 months, 60% by\u00a02 years Subdermal etonogestrel implant: 13 to 22% GnRH agonists: up to 96% Testosterone: undefined [3]", "contents": "Menstrual Suppression -- Clinical Significance. By utilizing menstrual suppression methods, amenorrhea or oligomenorrhea may be achieved, and the described negative impacts of menses may be mitigated\u00a0(see discussion of the impact on special populations in Indications ). Rates of amenorrhea per method are as follows: OCPs: 88% by 12 months POPs: widely variable depending on formulation and dose, 10\u00a0to 76% DMPA: up to 71% by\u00a02 years Levonorgestrel-releasing IUD: 50% by 12 months, 60% by\u00a02 years Subdermal etonogestrel implant: 13 to 22% GnRH agonists: up to 96% Testosterone: undefined [3]"}
{"id": "article-154122_112", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes", "content": "Menstruating individuals may seek menstrual healthcare in various settings, ranging from community health clinics to large medical centers. These settings include primary care offices with family medicine or internal medicine physicians, general pediatricians, physician assistants, or nurse practitioners, as well as specialty care clinics with gynecologists, nurse midwives, adolescent or developmental pediatricians, or adult or pediatric endocrinologists. It is crucial for healthcare team members in these settings to have a comprehensive understanding of the indications and methods of menstrual suppression and to offer this option to their patients if desired.", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes. Menstruating individuals may seek menstrual healthcare in various settings, ranging from community health clinics to large medical centers. These settings include primary care offices with family medicine or internal medicine physicians, general pediatricians, physician assistants, or nurse practitioners, as well as specialty care clinics with gynecologists, nurse midwives, adolescent or developmental pediatricians, or adult or pediatric endocrinologists. It is crucial for healthcare team members in these settings to have a comprehensive understanding of the indications and methods of menstrual suppression and to offer this option to their patients if desired."}
{"id": "article-154122_113", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes", "content": "Individual beliefs about menstrual suppression being \"unnatural\" or \"unhealthy\" create a barrier to menstrual suppression implementation. [5] Up to 40% of interviewed American women express the belief that reduced frequency of menses has negative bodily impacts (such as decreased fertility), and nearly half express the belief that menses is important to \"rid the body of menstrual build-up.' [5] This belief is demonstrated more strongly among black and Hispanic women than white women and may vary in intensity or reasoning between cultures. [22] [3]", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes. Individual beliefs about menstrual suppression being \"unnatural\" or \"unhealthy\" create a barrier to menstrual suppression implementation. [5] Up to 40% of interviewed American women express the belief that reduced frequency of menses has negative bodily impacts (such as decreased fertility), and nearly half express the belief that menses is important to \"rid the body of menstrual build-up.' [5] This belief is demonstrated more strongly among black and Hispanic women than white women and may vary in intensity or reasoning between cultures. [22] [3]"}
{"id": "article-154122_114", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes", "content": "There is no current evidence to support these beliefs. These beliefs may reflect a general lack of understanding or access to information among menstruating persons regarding the physiology of the menstrual cycle and hormonal contraceptives, as well as the absence or poor quality of counseling by clinicians on menstrual health. Clinicians may not have substantial knowledge or exposure to hormonal contraceptives for menstrual suppression or may only be familiar with the historical 28-day cyclic method. [4] Clinicians who provide gynecologic healthcare should counsel patients with evidence-based information regarding the safety, benefits, and risks of menstrual suppression in a way that acknowledges their beliefs and eases their concerns. [3]", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes. There is no current evidence to support these beliefs. These beliefs may reflect a general lack of understanding or access to information among menstruating persons regarding the physiology of the menstrual cycle and hormonal contraceptives, as well as the absence or poor quality of counseling by clinicians on menstrual health. Clinicians may not have substantial knowledge or exposure to hormonal contraceptives for menstrual suppression or may only be familiar with the historical 28-day cyclic method. [4] Clinicians who provide gynecologic healthcare should counsel patients with evidence-based information regarding the safety, benefits, and risks of menstrual suppression in a way that acknowledges their beliefs and eases their concerns. [3]"}
{"id": "article-154122_115", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Parent and Caregiver Involvement", "content": "For adolescents, the involvement of a parent or caregiver can be considered. Clinicians should encourage prioritization of adolescent autonomy when counseling adolescents and parents or caregivers on menstrual suppression options. [57] In some circumstances, the adolescent does not prefer parent or caregiver involvement. In the U.S., many states' laws allow adolescents to obtain contraceptives and sexual healthcare without parental involvement or consent. Clinicians must be mindful of specific local laws, summarized and frequently updated by the Guttmacher Institute on sexual and reproductive health policy and can be reviewed\u00a0on their website.", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Parent and Caregiver Involvement. For adolescents, the involvement of a parent or caregiver can be considered. Clinicians should encourage prioritization of adolescent autonomy when counseling adolescents and parents or caregivers on menstrual suppression options. [57] In some circumstances, the adolescent does not prefer parent or caregiver involvement. In the U.S., many states' laws allow adolescents to obtain contraceptives and sexual healthcare without parental involvement or consent. Clinicians must be mindful of specific local laws, summarized and frequently updated by the Guttmacher Institute on sexual and reproductive health policy and can be reviewed\u00a0on their website."}
{"id": "article-154122_116", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Parent and Caregiver Involvement", "content": "In individuals with developmental or physical disabilities, caregivers\u00a0may be involved in decision-making or the sole decision-maker. When individuals with disabilities are cognitively impaired or have unclear decision-making capacity, clinicians should discuss management plans with those who have legal guardianship or medical decision-making power for the patient. [26] The\u00a0clinician should guide the caregiver\u00a0in considering the benefits and risks for the individual and prioritize the patient's personal preferences and values over the caregivers'. [58] Decisions made on behalf of individuals with disabilities regarding menstrual\u00a0suppression should maximize patient autonomy and avoid harm. [25]", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Parent and Caregiver Involvement. In individuals with developmental or physical disabilities, caregivers\u00a0may be involved in decision-making or the sole decision-maker. When individuals with disabilities are cognitively impaired or have unclear decision-making capacity, clinicians should discuss management plans with those who have legal guardianship or medical decision-making power for the patient. [26] The\u00a0clinician should guide the caregiver\u00a0in considering the benefits and risks for the individual and prioritize the patient's personal preferences and values over the caregivers'. [58] Decisions made on behalf of individuals with disabilities regarding menstrual\u00a0suppression should maximize patient autonomy and avoid harm. [25]"}
{"id": "article-154122_117", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Multi-Disciplinary Teams in Caring for Transgender and Gender-Diverse\u00a0Individuals", "content": "As discussed in Special Populations , transgender and gender-diverse individuals should be\u00a0cared for\u00a0by an interprofessional team with medical and mental health professionals specializing in gender-affirming care. [32] [36] [59] Mental health professionals are an important team component as they can facilitate shared decision-making, support both the individual and caregiver, if applicable, through the treatment course, and perform a biopsychosocial assessment before treatment initiation. [36]", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Multi-Disciplinary Teams in Caring for Transgender and Gender-Diverse\u00a0Individuals. As discussed in Special Populations , transgender and gender-diverse individuals should be\u00a0cared for\u00a0by an interprofessional team with medical and mental health professionals specializing in gender-affirming care. [32] [36] [59] Mental health professionals are an important team component as they can facilitate shared decision-making, support both the individual and caregiver, if applicable, through the treatment course, and perform a biopsychosocial assessment before treatment initiation. [36]"}
{"id": "article-154122_118", "title": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Disclosures", "content": "The views expressed in this article are those of the authors and do not reflect the official policy of Evans Army Community Hospital, Womack Army Medical Center, the Department of the Army, the U.S. Department of Defense, or the U.S. Government.", "contents": "Menstrual Suppression -- Enhancing Healthcare Team Outcomes -- Disclosures. The views expressed in this article are those of the authors and do not reflect the official policy of Evans Army Community Hospital, Womack Army Medical Center, the Department of the Army, the U.S. Department of Defense, or the U.S. Government."}
{"id": "article-154122_119", "title": "Menstrual Suppression -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Menstrual Suppression -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}